Medtronic (MDT) 10-Q 7 Sep 16 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jul. 29, 2016	Aug. 26, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Medtronic plc
Entity Central Index Key	1,613,103
Document Period End Date	Jul. 29, 2016
Current Fiscal Year End Date	--04-28
Document Type	10-Q
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Ordinary Shares Outstanding		1,381,935,603
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,017

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Income Statement [Abstract]
Net sales	$ 7,166	$ 7,274
Costs and expenses:
Cost of products sold	2,261	2,456
Research and development expense	556	558
Selling, general, and administrative expense	2,428	2,449
Restructuring charges, net	94	67
Certain litigation charges	82	0
Acquisition-related items	52	71
Amortization of intangible assets	487	481
Other expense, net	39	61
Operating profit	1,167	1,131
Interest income	(93)	(115)
Interest expense	272	306
Interest expense, net	179	191
Income from operations before income taxes	988	940
Provision for income taxes	59	120
Net income	$ 929	$ 820
Basic earnings per share (usd per share)	$ 0.67	$ 0.58
Diluted earnings per share (usd per share)	$ 0.66	$ 0.57
Basic weighted average shares outstanding (shares)	1,392.2	1,418.1
Diluted weighted average shares outstanding (shares)	1,407.1	1,436.4
Cash dividends declared per ordinary share (usd per share)	$ 0.43	$ 0.38

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 929	$ 820
Other comprehensive loss, net of tax:
Unrealized gain (loss) on available-for-sale securities, net of tax expense (benefit) of $52 and $(74), respectively	115	(131)
Currency adjustment, net	(350)	(26)
Net change in retirement obligations, net of tax expense of and $2 and $10, respectively	25	13
Unrealized gain (loss) on derivatives, net of tax expense (benefit) of $30 and $(20), respectively	54	(28)
Other comprehensive loss	(156)	(172)
Comprehensive income	$ 773	$ 648

Consolidated Statements of Com4

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Other Comprehensive Income (Loss), Tax
Unrealized gain (loss) on investments, tax expense (benefit)	$ 52	$ (74)
Net change in retirement obligations, tax expense	2	10
Unrealized gain (loss) on derivatives, tax expense (benefit)	$ 30	$ (20)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Current assets:
Cash and cash equivalents	$ 3,060	$ 2,876
Investments	9,750	9,758
Accounts receivable, less allowances of $161 and $161, respectively	5,357	5,562
Inventories	3,580	3,473
Other current assets	1,751	1,931
Total current assets	23,498	23,600
Property, plant, and equipment	9,917	9,714
Accumulated depreciation	(5,103)	(4,873)
Property, plant, and equipment, net	4,814	4,841
Goodwill	41,309	41,500
Other intangible assets, net	26,437	26,899
Tax assets	1,232	1,383
Other assets	1,311	1,421
Total assets	98,601	99,644
Current liabilities:
Current debt obligations	1,947	993
Accounts payable	1,615	1,709
Accrued compensation	1,205	1,712
Other accrued expenses	3,129	2,751
Total current liabilities	7,896	7,165
Long-term debt	30,124	30,109
Accrued compensation and retirement benefits	1,770	1,759
Accrued income taxes	2,344	2,903
Deferred tax liabilities	3,790	3,729
Other liabilities	1,785	1,916
Total liabilities	47,709	47,581
Commitments and contingencies
Shareholders’ equity:
Ordinary shares— par value $0.0001	0	0
Retained earnings	52,848	53,931
Accumulated other comprehensive loss	(2,024)	(1,868)
Total shareholders’ equity	50,824	52,063
Noncontrolling interests	68	0
Total equity	50,892	52,063
Total liabilities and equity	$ 98,601	$ 99,644

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 161	$ 161
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Operating Activities:
Net income	$ 929	$ 820
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	737	701
Amortization of debt discount and issuance costs	7	7
Acquisition-related items	(5)	232
Provision for doubtful accounts	9	10
Deferred income taxes	32	(159)
Stock-based compensation	79	96
Other, net	(85)	(39)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	196	279
Inventories	(101)	(207)
Accounts payable and accrued liabilities	(361)	(424)
Other operating assets and liabilities	50	(408)
Certain litigation charges	82	0
Certain litigation payments	(19)	(92)
Net cash provided by operating activities	1,550	816
Investing Activities:
Acquisitions, net of cash acquired	(12)	(179)
Additions to property, plant, and equipment	(330)	(224)
Purchases of investments	(1,044)	(1,851)
Sales and maturities of investments	1,104	1,266
Other investing activities, net	(2)	2
Net cash used in investing activities	(284)	(986)
Financing Activities:
Acquisition-related contingent consideration	(11)	(3)
Change in current debt obligations, net	926	429
Issuance of long-term debt	33	0
Payments on long-term debt	(17)	(1,004)
Dividends to shareholders	(599)	(538)
Issuance of ordinary shares	214	98
Repurchase of ordinary shares	(1,763)	(750)
Other financing activities	57	24
Net cash used in financing activities	(1,160)	(1,744)
Effect of exchange rate changes on cash and cash equivalents	78	50
Net change in cash and cash equivalents	184	(1,864)
Cash and cash equivalents at beginning of period	2,876	4,843
Cash and cash equivalents at end of period	3,060	2,979
Supplemental Cash Flow Information
Cash paid for income taxes	115	636
Cash paid for interest	$ 68	$ 76

Basis of Presentation

Basis of Presentation	3 Months Ended
	Jul. 29, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic or the Company) for the periods presented. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. The Company’s fiscal years 2017 , 2016 , and 2015 will end or ended on April 28, 2017 , April 29, 2016 , and April 24, 2015 , respectively.

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	Jul. 29, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted In April 2015, the Financial Accounting Standards Board (FASB) issued accounting guidance that requires debt issuance costs to be presented in the balance sheet as a direct deduction from the related debt liability. Prior to this amendment, debt issuance costs were recognized as an asset in the balance sheet and did not offset the related debt liability. The Company retrospectively adopted this guidance in the first quarter of fiscal year 2017. Its adoption had an impact of $133 million and $138 million on the Company's consolidated balance sheets at July 29, 2016 and April 29, 2016 , respectively. Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s consolidated financial statements. In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is evaluating the impact of the equity investment guidance on the Company's consolidated financial statements. In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements. In March 2016, the FASB issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefit and deficiencies as additional paid-in capital. For the three months ended July 29, 2016, the Company recognized $57 million of excess tax benefits in additional paid-in capital. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018.

Acquisitions and Acquisition-Re

Acquisitions and Acquisition-Related Items	3 Months Ended
	Jul. 29, 2016
Business Combinations [Abstract]
Acquisitions and Acquisition-Related Items	Acquisitions and Acquisition-Related Items The Company had various acquisitions and other acquisition-related activity during the first quarter of fiscal years 2017 and 2016 . Certain acquisitions were accounted for as business combinations as noted below. In accordance with authoritative guidance on business combination accounting, the assets and liabilities of the businesses acquired were recorded and consolidated as of the acquisition date at their respective fair values. Unless otherwise disclosed, the pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the results of the Company for the three months ended July 29, 2016 or July 31, 2015 . The results of operations related to each business acquired have been included in the Company's consolidated statements of income since the date each business was acquired. Fiscal Year 2017 The fair values of the assets acquired and liabilities assumed during the three months ended July 29, 2016 were as follows: (in millions) Other current assets $ 8 Property, plant, and equipment 5 Other intangible assets 48 Goodwill 56 Total assets acquired 117 Current liabilities 3 Deferred tax liabilities 3 Other liabilities 3 Total liabilities assumed 9 Net assets acquired $ 108 The Company accounted for the acquisitions above as business combinations using the acquisition method of accounting. Acquisition-Related Items During the three months ended July 29, 2016 and July 31, 2015 , the Company recognized acquisition-related items expense of $52 million and $71 million , respectively, primarily due to integration-related costs incurred in connection with the Covidien acquisition. Subsequent Acquisitions On August 23, 2016, the Company's Cardiac and Vascular Group acquired HeartWare International, Inc. for total consideration of approximately $1.1 billion . The addition of HeartWare International, Inc.'s portfolio of heart failure products expands and strengthens the Company's heart failure product offerings and further complements its existing global cardiac rhythm and heart failure business. On August 5, 2016, the Company's Minimally Invasive Therapies Group acquired Smith & Nephew's gynecology business for total consideration of approximately $350 million . The addition of Smith & Nephew's gynecology business expands and strengthens Medtronic's minimally invasive surgical offerings and further complements its existing global gynecology business. Contingent Consideration Certain of the Company’s business combinations involve the potential for the payment of future consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired business reaching certain performance milestones, including attaining specified revenue levels or achieving product development targets. For business combinations subsequent to April 24, 2009, a liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value recognized as income or expense within acquisition-related items in the consolidated statements of income. The Company measures the liability on a recurring basis using Level 3 inputs. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. Changes in projected revenues, probabilities of payment, discount rates, or projected payment dates may result in adjustments to the fair value measurement. The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at (in millions) July 29, 2016 Valuation Technique Unobservable Input Range Discount rate 11% - 32.5% Revenue-based payments $194 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2017 - 2025 Discount rate 0.3% - 5.5% Product development-based payments $185 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2017 - 2025 At July 29, 2016 , the estimated maximum potential amount of undiscounted future contingent consideration payments that the Company is expected to make associated with all completed business combinations or purchases of intellectual property prior to April 24, 2009 was approximately $175 million . The Company estimates the milestones or other conditions associated with the contingent consideration will be reached in fiscal year 2017 and thereafter. The fair value of contingent consideration associated with acquisitions subsequent to April 24, 2009, at July 29, 2016 and April 29, 2016 , was $379 million and $377 million , respectively. At July 29, 2016 , $321 million was reflected in other liabilities and $58 million was reflected in other accrued expenses in the consolidated balance sheets. At April 29, 2016 , $311 million was reflected in other liabilities and $66 million was reflected in other accrued expenses in the consolidated balance sheets. The portion of the contingent consideration paid related to the acquisition date fair value is reported as financing activities in the consolidated statements of cash flows. Amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended (in millions) July 29, 2016 July 31, 2015 Beginning Balance $ 377 $ 264 Purchase price contingent consideration 21 26 Payments (14 ) (3 ) Change in fair value (5 ) 4 Ending Balance $ 379 $ 291

Restructuring Charges, Net

Restructuring Charges, Net	3 Months Ended
	Jul. 29, 2016
Restructuring and Related Activities [Abstract]
Restructuring Charges, Net	Restructuring Charges, Net Cost Synergies Initiative The cost synergies initiative is the Company's restructuring program primarily related to the integration of Covidien. This initiative is expected to contribute to the approximately $850 million in cost synergies expected to be achieved as a result of the integration of the Covidien acquisition through fiscal year 2018, including administrative office optimization, manufacturing and supply chain infrastructure, certain program cancellations, and certain general and administrative savings. Restructuring charges are expected to be incurred on a quarterly basis throughout fiscal year 2017 and in future fiscal years as cost synergy strategies are finalized. A summary of the restructuring accrual, recorded within other accrued expenses and other liabilities in the consolidated balance sheets, and related activity is presented below: (in millions) Employee Termination Costs Asset Write-downs Other Costs Total April 29, 2016 $ 213 $ — $ 37 $ 250 Restructuring charges 77 14 20 111 Payments/write-downs (68 ) (14 ) (16 ) (98 ) Reversal of excess accrual (8 ) — 1 (7 ) July 29, 2016 $ 214 $ — $ 42 $ 256 As a result of certain employees identified for termination finding other positions within the Company, the Company recorded a $7 million reversal of excess restructuring reserves for the three months ended July 29, 2016 . As part of the cost synergies initiative, the Company recorded $14 million of asset write-downs for the three months ended July 29, 2016 , which included $10 million related to inventory write-offs of discontinued product lines, and, therefore, was recognized within cost of products sold in the consolidated statements of income. For the three months ended July 29, 2016 , asset write-downs included $4 million related to property, plant, and equipment impairments. The Company did not recognize any significant impairments during the three months ended July 31, 2015 .

Financial Instruments

Financial Instruments	3 Months Ended
	Jul. 29, 2016
Investments [Abstract]
Financial Instruments	Financial Instruments The Company holds investments consisting primarily of marketable debt and equity securities. The authoritative guidance is principally applied to financial assets and liabilities, such as marketable equity securities and debt and equity securities, that are classified and accounted for as trading and available-for-sale and are measured on a recurring basis. Further, we also hold cost or equity method investments which are measured at fair value on a nonrecurring basis. The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at July 29, 2016 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 675 $ 28 $ — $ 703 $ 703 $ — Marketable equity securities 85 45 (1 ) 129 — 129 Total Level 1 760 73 (1 ) 832 703 129 Level 2: Corporate debt securities 4,113 123 (14 ) 4,222 4,222 — U.S. government and agency securities 914 3 — 917 917 — Mortgage-backed securities 917 26 (16 ) 927 927 — Foreign government and agency securities 15 — — 15 15 — Other asset-backed securities 230 3 — 233 233 — Debt funds 2,872 14 (246 ) 2,640 2,640 — Total Level 2 9,061 169 (276 ) 8,954 8,954 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Total available-for-sale securities $ 9,869 $ 242 $ (280 ) $ 9,831 $ 9,657 $ 174 Trading securities: Level 1: Exchange-traded funds 75 19 (1 ) 93 93 — Total Level 1 75 19 (1 ) 93 93 — Total trading securities $ 75 $ 19 $ (1 ) $ 93 $ 93 $ — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 546 — — N/A — 546 Total Level 3 546 — — N/A — 546 Total cost method, equity method, and other investments $ 546 $ — $ — N/A $ — $ 546 Total investments $ 10,490 $ 261 $ (281 ) $ 9,924 $ 9,750 $ 720 The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 29, 2016 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 792 $ 14 $ (1 ) $ 805 $ 805 $ — Marketable equity securities 75 21 (11 ) 85 — 85 Total Level 1 867 35 (12 ) 890 805 85 Level 2: Corporate debt securities 3,935 85 (24 ) 3,996 3,996 — U.S. government and agency securities 902 2 — 904 904 — Mortgage-backed securities 1,016 17 (18 ) 1,015 1,015 — Other asset-backed securities 192 3 — 195 195 — Debt funds 3,040 5 (281 ) 2,764 2,764 — Total Level 2 9,085 112 (323 ) 8,874 8,874 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Total available-for-sale securities $ 10,000 $ 147 $ (338 ) $ 9,809 $ 9,679 $ 130 Trading securities: Level 1: Exchange-traded funds 65 15 (1 ) 79 79 — Total Level 1 65 15 (1 ) 79 79 — Total trading securities $ 65 $ 15 $ (1 ) $ 79 $ 79 $ — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 506 — — N/A — 506 Total Level 3 506 — — N/A — 506 Total cost method, equity method, and other investments $ 506 $ — $ — N/A $ — $ 506 Total investments $ 10,571 $ 162 $ (339 ) $ 9,888 $ 9,758 $ 636 Marketable Debt and Equity Securities The following tables represents the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 29, 2016 and April 29, 2016 : July 29, 2016 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 494 $ (6 ) $ 216 $ (8 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 208 (6 ) 121 (10 ) Debt funds 851 — 1,789 (246 ) Marketable equity securities $ 4 $ (1 ) $ — $ — Total $ 1,557 $ (13 ) $ 2,170 $ (267 ) April 29, 2016 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 756 $ (18 ) $ 136 $ (6 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 196 (5 ) 92 (5 ) U.S. government and agency securities 308 (4 ) 67 (5 ) Debt funds 670 (26 ) 1,601 (256 ) Marketable equity securities 45 (11 ) — — Total $ 1,975 $ (64 ) $ 1,940 $ (275 ) The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at July 29, 2016 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6% The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three months ended July 29, 2016 or July 31, 2015 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): (in millions) Total Level 3 Corporate Debt Auction Rate April 29, 2016 $ 45 $ 1 $ 44 Total unrealized losses included in other comprehensive income — — — July 29, 2016 $ 45 $ 1 $ 44 (in millions) Total Level 3 Corporate Debt Auction Rate April 24, 2015 $ 106 $ 1 $ 105 Total unrealized losses included in other comprehensive income (3 ) — (3 ) July 31, 2015 $ 103 $ 1 $ 102 Activity related to the Company’s investment portfolio is as follows: Three months ended July 29, 2016 July 31, 2015 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 1,098 $ 6 $ 1,237 $ 29 Gross realized gains 7 4 5 12 Gross realized losses (12 ) — (5 ) — Impairment losses recognized — (3 ) — (23 ) (1) Includes available-for-sale debt securities. (2) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments. Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. At July 29, 2016 and April 29, 2016 , the credit loss portion of other-than temporary impairments on debt securities was not significant. The total reductions of available-for-sale debt securities sold during the three months ended July 29, 2016 and July 31, 2015 were not significant. The total other-than-temporary impairment losses on available-for-sale debt securities for the three months ended July 29, 2016 and July 31, 2015 were not significant. The July 29, 2016 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) July 29, 2016 Due in one year or less $ 969 Due after one year through five years 3,188 Due after five years through ten years 2,845 Due after ten years 60 Total $ 7,062 The Company holds investments in marketable equity securities, which are classified as other assets in the consolidated balance sheets. The aggregate carrying amount of these investments was $129 million and $85 million at July 29, 2016 and April 29, 2016 , respectively. The Company did not recognize any significant impairment charges related to marketable equity securities during the three months ended July 29, 2016 . During the three months ended July 31, 2015 , the Company determined that the fair values of certain marketable equity securities were below the carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $20 million in impairment charges for the three months ended July 31, 2015 , which were recognized within other expense, net in the consolidated statements of income. Cost method, equity method, and other investments The Company holds investments in equity and other securities that are accounted for using the cost or equity method, which are classified as other assets in the consolidated balance sheets. At July 29, 2016 and April 29, 2016 , the aggregate carrying amount of equity and other securities without a quoted market price and accounted for using the cost or equity method was $546 million and $506 million , respectively. Cost and equity method investments are measured at fair value on a nonrecurring basis. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The values of cost and equity method investments are not assessed for impairment if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment. During the three months ended July 29, 2016 , the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $3 million in impairment charges during the three months ended July 29, 2016 , which were recognized in other expense, net in the consolidated statements of income. The Company did not recognize any significant impairment charges related to cost method investments during the three months ended July 31, 2015 . Cost method investments fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value, as the investments are in privately-held entities without quoted market prices. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the entities, including financial statements and market participant valuations from recent and proposed equity offerings.

Financing Arrangements

Financing Arrangements	3 Months Ended
	Jul. 29, 2016
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. Commercial paper amounts outstanding at July 29, 2016 totaled $975 million . No amounts were outstanding at April 29, 2016 . During the three months ended July 29, 2016 , the weighted average original maturity of the commercial paper outstanding was approximately 21 days, and the weighted average interest rate was 0.73 percent. The issuance of commercial paper proportionately reduced the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.5 billion five year credit facility (Credit Facility) which provides back up funding for the commercial paper program described above. At July 29, 2016 and April 29, 2016 , no amounts were outstanding. Interest rates are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreement also contains customary covenants, all of which the Company remained in compliance with at July 29, 2016 . Long-Term Debt Long-term debt consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year July 29, 2016 April 29, 2016 6.000 percent ten-year 2008 CIFSA senior notes 2018 $ 1,150 $ 1,150 1.500 percent three-year 2015 senior notes 2018 1,000 1,000 1.375 percent five-year 2013 senior notes 2018 1,000 1,000 5.600 percent ten-year 2009 senior notes 2019 400 400 4.450 percent ten-year 2010 senior notes 2020 766 766 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 530 530 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 4.375 percent twenty-year 2015 senior notes 2035 2,382 2,382 6.550 percent thirty-year 2008 CIFSA senior notes 2038 374 374 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 325 325 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,000 4,000 Three-year term loan 2018 3,000 3,000 Interest rate swaps (Note 7) 2018 - 2022 106 89 Capital lease obligations 2018 - 2025 25 26 Bank borrowings 2021 66 56 Debt premium 2018 - 2045 198 214 Deferred Financing Costs (1) 2018-2045 (133 ) (138 ) Total Long-Term Debt $ 30,124 $ 30,109 (1) We retrospectively adopted the guidance to simplify the presentation of deferred issuance costs in the quarter ending July 29, 2016. As a result deferred issuance costs have been reclassified from other assets to long-term debt. See Note 2 to the consolidated financial statements for additional information. Senior Notes The Company has outstanding unsecured senior obligations including those described as senior notes in the long-term debt table above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at July 29, 2016 . The Company used the net proceeds from the sale of the Senior Notes primarily for working capital and general corporate uses, which includes the repayment of other indebtedness of the Company, and to fund the acquisition of Covidien in fiscal year 2015. For additional information regarding the terms of these agreements, refer to Note 7 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . Financial Instruments Not Measured at Fair Value At July 29, 2016 , the total estimated fair value of the Company’s long-term debt, including the current portion, was $30.5 billion compared to a principal value of $27.4 billion ; at April 29, 2016 , the total estimated fair value was $29.8 billion compared to a principal value of $27.4 billion . The fair value was estimated using quoted market prices for the publicly registered senior notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and derivative/hedging activity.

Derivatives and Foreign Exchang

Derivatives and Foreign Exchange Risk Management	3 Months Ended
	Jul. 29, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Foreign Exchange Risk Management	Derivatives and Currency Exchange Risk Management The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro and Japanese Yen. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding at July 29, 2016 and April 29, 2016 was $10.7 billion and $10.8 billion , respectively. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets, statements of income, and statements of cash flows. Freestanding Derivative Contracts Freestanding derivative contracts are used to offset the Company’s exposure to the change in value of specific foreign currency denominated assets and liabilities and to offset variability of cash flows associated with forecasted transactions denominated in a foreign currency. The gross notional amount of these contracts, not designated as hedging instruments, outstanding at July 29, 2016 and April 29, 2016 , was $4.9 billion and $5.0 billion , respectively. The amounts and classification of the (losses) gains in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three months ended July 29, 2016 and July 31, 2015 were as follows: (in millions) Three months ended Derivatives Not Designated as Hedging Instruments Classification July 29, 2016 July 31, 2015 Currency exchange rate contracts (losses) gains Other expense, net $ (3 ) $ 20 Cash Flow Hedges Currency Exchange Rate Risk Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. No gains or losses relating to ineffectiveness of foreign currency cash flow hedges were recognized in earnings during the three months ended July 29, 2016 or July 31, 2015 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were derecognized or discontinued during the three months ended July 29, 2016 or July 31, 2015 . The gross notional amount of these contracts, designated as cash flow hedges, outstanding at July 29, 2016 and April 29, 2016 , was $5.8 billion and $5.7 billion , respectively, and will mature within the subsequent three -year period. The amount of gains (losses) and location of the gains (losses) in the consolidated statements of income and other comprehensive (loss) income (OCI) related to currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended July 29, 2016 and July 31, 2015 were as follows: Three months ended July 29, 2016 Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income (in millions) Derivatives in Cash Flow Hedging Relationships Amount Classification Amount Currency exchange rate contracts $ 121 Other expense, net $ 15 Three months ended July 31, 2015 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Classification Amount Currency exchange rate contracts $ (14 ) Other expense, net $ 95 Cost of products sold (21 ) Total $ (14 ) $ 74 Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. No gains or losses relating to ineffectiveness of forward starting interest rate derivative instruments were recognized in earnings during the three months ended July 29, 2016 or July 31, 2015 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness during the three months ended July 29, 2016 or July 31, 2015 . At July 29, 2016 , the Company had $300 million of fixed pay, forward starting interest rate swaps with a weighted average fixed-rate of 3.10 percent in anticipation of planned debt issuances in fiscal year 2017. For the three months ended July 29, 2016 and July 31, 2015 , the reclassification of the effective portion of the net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net was not significant. The unrealized losses on outstanding forward starting interest rate swap derivative instruments at July 29, 2016 and April 29, 2016 were $71 million and $48 million , respectively. Unrealized losses on outstanding forward starting interest rate swap derivative instruments were recorded in other liabilities, with the offset recorded in accumulated other comprehensive loss in the consolidated balance sheets. At July 29, 2016 and April 29, 2016 , the Company had $36 million and $90 million , respectively, in after-tax net unrealized losses associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $53 million of after-tax net unrealized gains as of July 29, 2016 will be reclassified into the consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. At July 29, 2016 and April 29, 2016 , the Company had interest rate swaps in gross notional amounts of $1.2 billion and $1.2 billion , respectively, designated as fair value hedges of underlying fixed-rate senior note obligations. For additional information regarding the terms of the Company’s interest rate swap agreements, refer to Note 8 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . At July 29, 2016 , the market value of outstanding interest rate swap agreements was a net $106 million unrealized gain, and the market value of the hedged item was a net $106 million unrealized loss. The amounts which were recorded in other assets, other current assets, and other liabilities with the offsets recorded in long-term debt and current debt obligations in the consolidated balance sheets. No significant hedge ineffectiveness was recorded as a result of these fair value hedges for the three months ended July 29, 2016 or July 31, 2015 . During the three months ended July 29, 2016 and July 31, 2015 , the Company did not have any significant ineffective fair value hedging instruments. In addition, during the three months ended July 29, 2016 and July 31, 2015 , the Company did not recognize any significant gains or losses on firm commitments that no longer qualify as fair value hedges. Balance Sheet Presentation The following tables summarize the balance sheet classification and fair value amounts of derivative instruments reported in the consolidated balance sheets at July 29, 2016 and April 29, 2016 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories. July 29, 2016 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets 191 Other accrued expenses 101 Interest rate contracts Other assets 106 Other liabilities 71 Currency exchange rate contracts Other assets 55 Other liabilities 55 Total derivatives designated as hedging instruments $ 352 $ 227 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets $ 26 Other accrued expenses $ 13 Cross currency interest rate contracts Other assets 10 Other liabilities 10 Total derivatives not designated as hedging instruments $ 36 $ 23 Total derivatives $ 388 $ 250 April 29, 2016 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 123 Other accrued expenses $ 89 Interest rate contracts Other assets 89 Other liabilities 48 Currency exchange rate contracts Other assets 9 Other liabilities 54 Total derivatives designated as hedging instruments $ 221 $ 191 Derivatives not designated as hedging instruments Commodity derivatives Other current assets $ — Other accrued expenses $ 1 Currency exchange rate contracts Other current assets 13 Other accrued expenses 23 Cross currency interest rate contracts Other assets 14 Other liabilities 4 Total derivatives not designated as hedging instruments $ 27 $ 28 Total derivatives $ 248 $ 219 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis at July 29, 2016 and April 29, 2016 . July 29, 2016 April 29, 2016 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 272 $ 116 $ 145 $ 103 Derivative liabilities 169 81 166 53 The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. July 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative Assets Currency exchange rate contracts $ 272 $ (189 ) $ — $ 83 Interest rate contracts 106 (20 ) — 86 Cross currency interest rate contracts 10 (5 ) — 5 $ 388 $ (214 ) $ — $ 174 Derivative Liabilities Currency exchange rate contracts $ (169 ) $ 146 $ — $ (23 ) Interest rate contracts (71 ) 63 — (8 ) Cross currency interest rate contracts (10 ) 5 — (5 ) $ (250 ) $ 214 $ — $ (36 ) Total $ 138 $ — $ — $ 138 April 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative Assets Currency exchange rate contracts $ 145 $ (98 ) $ (1 ) $ 46 Interest rate contracts 89 (20 ) — 69 Cross currency interest rate contracts 14 — — 14 $ 248 $ (118 ) $ (1 ) $ 129 Derivative Liabilities Currency exchange rate contracts $ (166 ) $ 85 $ 26 $ (55 ) Interest rate contracts (48 ) 34 — (14 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity contracts (1 ) — — (1 ) $ (219 ) $ 119 $ 26 $ (74 ) Total $ 29 $ 1 $ 25 $ 55

Inventories

Inventories	3 Months Ended
	Jul. 29, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for those items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, or other economic factors. Inventory balances were as follows: (in millions) July 29, 2016 April 29, 2016 Finished goods $ 2,346 $ 2,242 Work in-process 497 499 Raw materials 737 732 Total $ 3,580 $ 3,473

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	3 Months Ended
	Jul. 29, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	Goodwill and Other Intangible Assets, Net Goodwill The changes in the carrying amount of goodwill by reporting unit for the three months ended July 29, 2016 were as follows: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 29, 2016 $ 6,243 $ 23,784 $ 9,620 $ 1,853 $ 41,500 Goodwill as a result of acquisitions 27 (3 ) 32 — 56 Currency adjustment, net (11 ) (231 ) (5 ) — (247 ) July 29, 2016 $ 6,259 $ 23,550 $ 9,647 $ 1,853 $ 41,309 The Company assesses goodwill for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did not recognize any goodwill impairment during the three months ended July 29, 2016 or July 31, 2015 . Intangible Assets The gross carrying amount and accumulated amortization of intangible assets at July 29, 2016 and April 29, 2016 were as follows: July 29, 2016 April 29, 2016 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 18,614 $ (1,596 ) $ 18,596 $ (1,331 ) Purchased technology and patents 11,537 (3,173 ) 11,397 (2,976 ) Trademarks and tradenames 804 (425 ) 854 (403 ) Other 72 (34 ) 72 (31 ) Total $ 31,027 $ (5,228 ) $ 30,919 $ (4,741 ) Indefinite-lived: IPR&D $ 638 $ 721 The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not recognize any intangible asset impairments during the three months ended July 29, 2016 or July 31, 2015 . The Company assesses indefinite-lived intangibles for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The indefinite-lived intangibles impairment test requires the Company to perform an assessment involving several estimates about fair value. The Company calculates the excess of indefinite-lived intangibles asset fair values over their carrying values utilizing a discounted future cash flow analysis. During the three months ended July 29, 2016 and July 31, 2015 , the Company did not recognize any indefinite-lived intangibles impairments. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances or other failures to achieve a commercially viable product, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense for the three months ended July 29, 2016 and July 31, 2015 , was $487 million and $481 million , respectively. Estimated aggregate amortization expense by fiscal year based on the current carrying value of definite-lived intangible assets at July 29, 2016 , excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2017 $ 1,449 2018 1,905 2019 1,811 2020 1,763 2021 1,746 2022 1,705

Income Taxes

Income Taxes	3 Months Ended
	Jul. 29, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes During the first quarter of fiscal year 2017, the Company recognized a $31 million net benefit from certain tax adjustments. This net benefit was recognized within provision for income taxes in the consolidated statements of income. A $ 431 million tax benefit was recognized as the result of the resolution of Covidien’s previously disclosed Tyco International plc intercompany debt issues with the U.S. Tax Court and the Appeals Division of the U.S. Internal Revenue Service (IRS). This benefit was partially offset by a $371 million charge associated with the expected resolution with the IRS for the Ardian, CoreValve, Inc. and Ablation Frontiers, Inc. acquisition-related issues and the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico for certain businesses. This resolution does not include the businesses that are the subject of the Medtronic, Inc. U.S. Tax Court case for fiscal years 2005 and 2006. In addition, a $29 million charge was recognized in connection with the redemption of an intercompany minority interest. The Company’s effective tax rate for the three months ended July 29, 2016 was 6.0 percent compared to 12.8 percent for the three months ended July 31, 2015 . The decrease in the effective tax rate for the three months ended July 29, 2016 was primarily due to certain tax adjustments recognized during the quarter, finalization of certain tax returns, and changes to uncertain tax position reserves. At July 29, 2016 , the Company's gross unrecognized tax benefits were $1.9 billion , compared to $2.7 billion at April 29, 2016. In addition, the Company accrued gross interest and penalties of $261 million at July 29, 2016 . If all of the Company’s unrecognized tax benefits were recognized, approximately $1.8 billion would impact the Company’s effective tax rate. The Company has recorded all of the gross unrecognized tax benefits as a non-current liability within accrued income taxes in the consolidated balance sheets. The Company will continue to recognize interest and penalties related to income tax matters within provision for income taxes in the consolidated statements of income and record the liability within accrued income taxes in the consolidated balance sheets. See Note 15 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Jul. 29, 2016
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Three months ended (in millions, except per share data) July 29, 2016 July 31, 2015 Numerator: Net income attributable to ordinary shareholders $ 929 $ 820 Denominator: Basic – weighted average shares outstanding 1,392.2 1,418.1 Effect of dilutive securities: Employee stock options 10.5 13.2 Employee restricted stock units 3.9 5.0 Other 0.5 0.1 Diluted – weighted average shares outstanding 1,407.1 1,436.4 Basic earnings per share $ 0.67 $ 0.58 Diluted earnings per share $ 0.66 $ 0.57 The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 4 million and 1 million ordinary shares for the three months ended July 29, 2016 and July 31, 2015 , respectively, because their effect would be anti-dilutive on the Company’s earnings per share. Additionally, the calculation of weighted average diluted shares outstanding excludes approximately 5 million shares and approximately 20 million shares for the three months ended July 29, 2016 and July 31, 2015 respectively, because the performance criteria had not yet been met. The calculation of weighted average diluted shares outstanding excludes approximately 1 million restricted stock units for each of the three months ended July 29, 2016 and July 31, 2015 , because the performance criteria had not yet been met.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Jul. 29, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock awards, and employee stock purchase plan shares recognized for the three months ended July 29, 2016 and July 31, 2015 : Three months ended (in millions) July 29, 2016 July 31, 2015 Stock options $ 38 $ 57 Restricted stock awards 34 34 Employee stock purchase plan shares 7 5 Total stock-based compensation expense $ 79 $ 96 Cost of products sold $ 11 $ 12 Research and development expense 9 8 Selling, general, and administrative expense 51 49 Restructuring charges, net 1 8 Acquisition-related items 7 19 Total stock-based compensation expense $ 79 $ 96 Income tax benefits (21 ) (29 ) Total stock-based compensation expense, net of tax $ 58 $ 67

Retirement Benefit Plans

Retirement Benefit Plans	3 Months Ended
	Jul. 29, 2016
Compensation and Retirement Disclosure [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three months ended July 29, 2016 and July 31, 2015 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) July 29, 2016 July 31, 2015 July 29, 2016 July 31, 2015 Service cost $ 29 $ 30 $ 19 $ 22 Interest cost 27 31 6 9 Expected return on plan assets (47 ) (45 ) (12 ) (13 ) Amortization of net actuarial loss 23 24 4 6 Net periodic benefit cost $ 32 $ 40 $ 17 $ 24

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure	3 Months Ended
	Jul. 29, 2016
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss) and Supplemental Equity Disclosure	Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure Changes in AOCI by component are as follows: (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities (1) Cumulative Translation Adjustments (2) Net Change in Retirement Obligations (3) Unrealized Gain (Loss) on Derivatives (4) Total Accumulated Other Comprehensive (Loss) Income April 29, 2016, net of tax $ (107 ) $ (474 ) $ (1,197 ) $ (90 ) $ (1,868 ) Other comprehensive income (loss) before reclassifications, before tax 168 (350 ) — 98 (84 ) Tax expense (52 ) — — (36 ) (88 ) Other comprehensive income (loss) before reclassifications, net of tax 116 (350 ) — 62 (172 ) Reclassifications, before tax (1 ) — 27 (14 ) 12 Tax (expense) benefit — — (2 ) 6 4 Reclassifications, net of tax (1 ) — 25 (8 ) 16 Other comprehensive income (loss), net of tax 115 (350 ) 25 54 (156 ) July 29, 2016, net of tax $ 8 $ (824 ) $ (1,172 ) $ (36 ) $ (2,024 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities (1) Cumulative Translation Adjustments (2) Net Change in Retirement Obligations (3) Unrealized Gain (Loss) on Derivatives (4) Total Accumulated Other Comprehensive (Loss) Income April 24, 2015, net of tax $ 14 $ (277 ) $ (1,131 ) $ 210 $ (1,184 ) Other comprehensive (loss) income before reclassifications, before tax (193 ) (26 ) (7 ) 14 (212 ) Tax benefit (expense) 70 — — (6 ) 64 Other comprehensive (loss) income before reclassifications, net of tax (123 ) (26 ) (7 ) 8 (148 ) Reclassifications, before tax (12 ) — 30 (62 ) (44 ) Tax benefit (expense) 4 — (10 ) 26 20 Reclassifications, net of tax (8 ) — 20 (36 ) (24 ) Other comprehensive (loss) income, net of tax (131 ) (26 ) 13 (28 ) (172 ) July 31, 2015, net of tax $ (117 ) $ (303 ) $ (1,118 ) $ 182 $ (1,356 ) (1) Represents net realized gains (losses) on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 5 ). (2) Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. (3) Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 13 ). (4) Relates to currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 7 ). The supplemental equity schedule below presents changes in the Company's noncontrolling interests and total shareholders' equity for the three months ended July 29, 2016 . (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 29, 2016 $ 52,063 $ — $ 52,063 Net income 929 — 929 Other comprehensive loss (156 ) — (156 ) Dividends to shareholders (599 ) — (599 ) Issuance of shares under stock purchase and award plans 214 — 214 Repurchase of ordinary shares (1,763 ) — (1,763 ) Tax benefit from exercise of stock-based awards 57 — 57 Stock-based compensation 79 — 79 Additions of noncontrolling ownership interests — 68 68 July 29, 2016 $ 50,824 $ 68 $ 50,892

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jul. 29, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations in the United States and around the world, including those described below. With respect to governmental proceedings and investigations, our standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures or result in lost revenues. The Company records a liability in the consolidated financial statements for loss contingencies related to legal actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company recognized an additional expense of $82 million in the first quarter of fiscal year 2017 related to probable and estimable damages. At July 29, 2016 and April 29, 2016 , accrued certain litigation charges were approximately $1.1 billion and $1.0 billion , respectively. The ultimate cost to the Company with respect to accrued certain litigation charges could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows. The Company includes accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets. In addition to litigation contingencies, the Company also has certain income tax and guarantee obligations that may potentially result in future costs. While it is not possible to predict the outcome for most of the matters discussed below, the Company believes it is possible that costs associated with them could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows. Product Liability Matters Sprint Fidelis In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. Pretrial proceedings are underway. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. INFUSE Litigation The Company estimates law firms representing approximately 6,000 claimants have asserted or intend to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of September 1, 2016, the Company has reached agreements to settle approximately 4,300 of these claims, and certain of the remaining claims are expected to proceed to trial beginning in fiscal year 2017. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. Other INFUSE Litigation On June 5, 2014, Humana, Inc. filed a lawsuit for unspecified monetary damages in the U.S. District Court for the Western District of Tennessee, alleging that Medtronic, Inc. violated federal racketeering (RICO) law and various state laws, by conspiring with physicians to promote unapproved uses of INFUSE. In September of 2015 the Court granted Medtronic’s motion to dismiss the primary allegations, including the RICO claims, in Humana’s complaint. In April of 2016 the Court denied Humana's motion to file an amended complaint. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Pelvic Mesh Litigation The Company, through the acquisition of Covidien, is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In July 2015, the Company and Bard agreed that Bard would pay the Company $121 million towards the settlement of 11,000 of these claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 15,800 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of September 1, 2016, the Company has reached agreements to settle approximately 6,200 of these claims. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. Patent Litigation Ethicon On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. In addition to claims of non-infringement, the Company asserts affirmative defenses of invalidity for each of the patents-in-suit. The case is currently in the early stages of fact discovery. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Shareholder Related Matters INFUSE On March 12, 2012, Charlotte Kokocinski (Kokocinski) filed a shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and directors in the U.S. District Court for the District of Minnesota, setting forth certain allegations, including a claim that defendants violated various purported duties in connection with the INFUSE bone graft product and otherwise. On March 25, 2013, the Court dismissed the case without prejudice, and Kokocinski subsequently filed an amended complaint. On March 30, 2015, the Court granted defendants’ motion to dismiss the amended complaint, dismissing the case with prejudice. Kokocinski sought reconsideration of that decision, and, on September 30, 2015, the Court denied Kokocinski’s request for reconsideration. Kokocinski has appealed the Court’s decision to the U.S. Court of Appeals for the Eighth Circuit. West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. The matters were consolidated in September, 2013, and in the consolidated complaint plaintiffs alleged a class period of September 28, 2010 through August 3, 2011. On September 30, 2015, the Court granted defendants’ motion for summary judgment in the consolidated matters. Plaintiffs have appealed the dismissal to the U.S. Court of Appeals for the Eighth Circuit. COVIDIEN ACQUISITION On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstein and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On December 30, 2014, a hearing was held on plaintiffs’ motion for preliminary injunction and on defendants’ motion to dismiss. On January 2, 2015, the District Court denied the plaintiffs’ motion for preliminary injunction and on January 5, 2015 issued its opinion. On March 20, 2015, the District Court issued its order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, reversed in part, and remanded the case to the District Court for further proceedings. In February of 2016, the Company petitioned the Minnesota Supreme Court to review the decision of the Minnesota State Court of Appeals, and on April 19, 2016 the Minnesota Supreme Court granted the Company’s petition on the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. A decision from the Minnesota Supreme Court is expected in calendar year 2017. The Company has not recognized an expense related to damages in connection with the shareholder related matters, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. Environmental Proceedings The Company, through the acquisition of Covidien, is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008. The compliance order included a directive to remove a significant volume of soils at the site. On December 19, 2008, Covidien filed an appeal with the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order. A hearing before the Maine Board began on January 25, 2010 and concluded on February 4, 2010. On August 19, 2010, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. On April 3, 2014, the Maine Supreme Judicial Court affirmed the Maine Board’s compliance order. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. The Company has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring Covidien to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that Covidien was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study and ordered Covidien to pay costs associated with the study. A report issued by the study panel contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations, and included preliminary cost estimates for a variety of potential remedial options, which the report describes as “very rough estimates of cost,” ranging from $25 million to $235 million . The report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. In June of 2014, a trial was held to determine if remediation was necessary and feasible, and on September 2, 2015, the District Court issued an order concluding that further engineering study and engineering design work is appropriate to determine the nature and extent of remediation in the Penobscot River and Bay. In January of 2016, the Court appointed an engineering firm to conduct the next phase of the study. The study is targeted for completion late calendar year 2017. The Company's accrued expenses for environmental proceedings are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. Government Matters Medtronic has received subpoenas or document requests from the Attorneys General in Massachusetts, California, Oregon, Illinois, and Washington seeking information regarding sales, marketing, clinical, and other information relating to the INFUSE bone graft product. The Company has not recognized an expense related to damages in connection with these matters, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. On May 2, 2011, the U.S. Attorney’s Office for the District of Massachusetts issued a subpoena to ev3, a subsidiary of the Company, requesting production of documents relating to sales and marketing and other issues in connection with several neurovascular products. The matters under investigation relate to activities prior to Covidien's acquisition of ev3 in 2010. ev3 complied as required with the subpoena and cooperated with the investigation. In the third quarter of fiscal year 2016, the Company accrued expenses in connection with this matter, which are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General and the U.S. Attorney’s Office for the Northern District of California, issued a subpoena requesting production of documents relating to sales and marketing practices associated with certain of ev3’s peripheral vascular products. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. Medtronic, Inc. filed a petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency. During October and November 2012, Medtronic, Inc. reached resolution with the IRS on various matters, including the deductibility of a settlement payment. Medtronic, Inc. and the IRS agreed to hold one issue, the calculation of amounts eligible for the one-time repatriation holiday, because such specific issue was being addressed by other taxpayers in litigation with the IRS. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court proceeding with respect to this issue began on February 3, 2015 and ended on March 12, 2015. On June 9, 2016, the U.S. Tax court issued its opinion with respect to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. An Appeal of the U.S. Tax Court Opinion must be filed within 90 days of the final decision by the Tax Court. The final decision will not occur until all issues related to the fiscal years are resolved. As one item remains open, the calculation of amounts eligible for the one-time repatriation holiday, a final decision is not expected until later this fiscal year. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. During the first quarter of fiscal year 2016, the Company finalized its agreement with the IRS on the proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon Inc. (Kyphon). The settlement was consistent with the certain tax adjustment recorded during the fourth quarter of fiscal year 2015. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2007 and 2008 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the tax effects of its acquisition structures for Ardian, CoreValve, Inc., and Ablation Frontiers, Inc. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2009, 2010, and 2011 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. The IRS continues to audit Medtronic, Inc.'s U.S. federal income tax returns for the fiscal years 2012 through 2014. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for the 2008 and 2009 tax years. The IRS continues to audit Covidien’s U.S. federal income tax returns for the years 2010 through 2012. Open periods for examination also include certain periods during which Covidien was a subsidiary of Tyco International plc (Tyco International). The resolution of these matters is subject to the conditions set forth in the Tyco tax sharing agreement (Tax Sharing Agreement). Tyco International has the right to administer, control and settle all U.S. income tax audits for periods prior to the 2007 separation. The IRS concluded its field examination of certain of Tyco International’s U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect Covidien’s income tax returns for certain years after 2000. Tyco International appealed certain of the tax adjustments proposed by the IRS and had resolved all but one of the matters associated with the proposed tax adjustments. The IRS asserted that substantially all of Tyco International’s intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on Tyco International’s U.S. income tax returns. The Company disagreed with the IRS’s proposed adjustments and, on July 22, 2013, Tyco International filed a petition with the U.S. Tax Court contesting the IRS assessment. On January 15, 2016, Tyco International, as audit managing party under the Tax Sharing Agreement, entered into Stipulations of Settled Issues with the IRS intended to resolve all Federal tax disputes related to this intercompany debt issue for the Tax Sharing Participants for the 1997 - 2000 audit cycle before the U.S. Tax Court. The Stipulations of Settled Issues were contingent upon the IRS Appeals Division applying the same settlement terms to all intercompany debt issues on appeal for subsequent audit cycles (2001 - 2007). On May 17, 2016 the IRS Office of Appeals issued fully executed Forms 870-AD that effectively settled the matters on appeal on the same terms as those set forth in the Stipulations of Settled Issues, and on May 31, 2016 the U.S. Tax Court entered decisions consistent with the Stipulations of Settled Issues. As a result, all aspects of this controversy that were before the U.S. Tax Court and Appeals Division of the IRS have been finally resolved for audit cycles from 1997-2007. See Note 10 for additional discussion of income taxes. Guarantees As a result of the acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International, TE Connectivity Ltd. (TE Connectivity), and Mallinckrodt plc (Mallinckrodt) which relate to certain contingent tax liabilities. On June 29, 2007, Covidien entered into the Tax Sharing Agreement, under which Covidien shares responsibility for certain of its, Tyco International’s, and TE Connectivity’s income tax liabilities for periods prior to Covidien’s 2007 separation from Tyco International (2007 separation). Covidien, Tyco International, and TE Connectivity share 42 percent , 27 percent , and 31 percent , respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to Covidien's, Tyco International’s, and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. In connection with the 2007 separation, all tax liabilities associated with Covidien business became Covidien’s tax liabilities. Following Covidien’s spin-off of its Pharmaceuticals business to Covidien shareholders through a distribution of all the outstanding ordinary shares of Mallinkrodt (2013 separation), Mallinckrodt became the primary obligor to the taxing authorities for the tax liabilities attributable to its subsidiaries, a significant portion of which relate to periods prior to the 2007 separation. However, Covidien remains the sole party subject to the Tax Sharing Agreement. Accordingly, Mallinckrodt does not share in the Company’s liability to Tyco International and TE Connectivity, nor in the receivable that the Company has from Tyco International, and TE Connectivity. If any party to the Tax Sharing Agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tax Sharing Agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of Covidien's, Tyco International’s and TE Connectivity’s tax liabilities. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to certain pre-2007 separation tax liabilities and tax years open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien, and/or TE Connectivity legal entities for periods prior to the 2007 separation. The resolutions with the U.S. Tax Court and IRS Appeals for fiscal years 1997 through 2007 were finalized during May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution. In conjunction with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, and Covidien indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to 2013 exceed $200 million , net of certain tax benefits realized. In addition, in connection with the 2013 separation, Covidien entered into certain other guarantee commitments and indemnifications with Mallinckrodt. See Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 for additional information. Except as described above in this note or for certain income tax related matters, the Company has not recognized an expense related to losses in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of them to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of the Company or its affiliates’ products or the negligence of any of their personnel or claims alleging that any of their products infringe third-party patents or other intellectual property. The Company’s maximum exposure under these indemnification provisions cannot be estimated, and the Company has not accrued any liabilities within the consolidated financial statements. Historically, the Company has not experienced significant losses on these types of indemnifications.

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Jul. 29, 2016
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment information The Company’s management evaluates performance and allocates resources based on profit and loss from operations before income taxes and interest expense, net, not including corporate determined charges, as presented in the table below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . In the first quarter of fiscal year 2017, the Company realigned the divisions within the Restorative Therapies Group. The Restorative Therapies Group consists of the following divisions: Spine, Brain Therapies, Pain Therapies, and Specialty Therapies. Net sales of the Company’s reportable segments include end-customer revenues from the sale of products each reportable segment develops and manufactures or distributes. Net sales and income from operations before income taxes by reportable segment are as follows: Three months ended (in millions) July 29, 2016 July 31, 2015 Cardiac and Vascular Group $ 2,518 $ 2,567 Minimally Invasive Therapies Group 2,424 2,456 Restorative Therapies Group 1,772 1,806 Diabetes Group 452 445 Total net sales $ 7,166 $ 7,274 Three months ended (in millions) July 29, 2016 July 31, 2015 Cardiac and Vascular Group $ 656 $ 817 Minimally Invasive Therapies Group 283 334 Restorative Therapies Group 507 481 Diabetes Group 112 117 Total reportable segments’ income from operations before income taxes 1,558 1,749 Impact of inventory step-up — (226 ) Restructuring charges, net (104 ) (67 ) Certain litigation charges (82 ) — Acquisition-related items (52 ) (71 ) Interest expense, net (179 ) (191 ) Corporate (153 ) (254 ) Total income from operations before income taxes $ 988 $ 940 Geographic information Net sales to external customers by geography are as follows: Three months ended (in millions) July 29, 2016 July 31, 2015 Americas (1) $ 4,297 $ 4,445 EMEA (2) 1,650 1,669 Asia-Pacific 822 770 Greater China 397 390 Total net sales $ 7,166 $ 7,274 (1) The U.S., which is included in the Americas, had net sales to external customers of $4.0 billion for the three months ended July 29, 2016 , and of $4.1 billion for the three months ended July 31, 2015 . (2) EMEA consists of the following regions: Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

Guarantor Financial Information

Guarantor Financial Information	3 Months Ended
	Jul. 29, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information Medtronic plc (Parent Company Guarantor) and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a Subsidiary Guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc. under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA) under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd. The guarantees provided by the Parent Company Guarantor and Subsidiary Guarantor(s) are joint and several. A summary of the guarantees is as follows: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. The following presents the Company’s Consolidating Statements of Comprehensive Income for the three months ended July 29, 2016 and July 31, 2015 , Condensed Consolidating Balance Sheets at July 29, 2016 and April 29, 2016 , and Condensed Consolidating Statements of Cash Flows for the three months ended July 29, 2016 and July 31, 2015 . Condensed consolidating financial information for the Parent Company Guarantor, Subsidiary Issuer, and Subsidiary Guarantor(s), on a stand-alone basis, is presented using the equity method of accounting. During the first quarter of fiscal year 2017, the Company undertook certain steps to reorganize ownership of various subsidiaries. The transactions were entirely among subsidiaries under the common control of Medtronic. This reorganization has been reflected as of the beginning of the earliest period presented. The Company made revisions to its condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 29, 2016 primarily due to an income statement error recognized in the second quarter of fiscal year 2016, resulting in an incorrect presentation of the investment in subsidiaries balances. In the condensed consolidating balance sheet of the guarantees of the Medtronic Senior Notes the $5.1 billion revision increased the line items Investment in Subsidiaries and Shareholders' Equity in the Subsidiary Issuer (Medtronic, Inc.) column. In the condensed consolidating balance sheet of the guarantees of the CIFSA Senior Notes the $5.1 billion revision decreased the line items Investment in Subsidiaries and Shareholders' Equity in the Subsidiary Issuer (CIFSA) column. Additionally, the Company revised the classification of a previously reported $20.5 billion intercompany payable balance in the Parent Guarantor (Medtronic plc) column. The $20.5 billion revision decreased the Investment in Subsidiaries and Intercompany Payable balances in the Parent Guarantor (Medtronic plc) column and decreased the Investment in Subsidiaries and Shareholders’ Equity balances in the Subsidiary Guarantor column in both the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes, decreased the Intercompany Receivable and Shareholders’ Equity balances in the Subsidiary Issuer (Medtronic, Inc.) column in the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes, and decreased the Intercompany Receivable and Shareholders’ Equity balances in the Subsidiary Non-Guarantors column in the condensed consolidating balance sheets of the guarantees of the CIFSA Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 29, 2016. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. Consolidating Statement of Comprehensive Income Three Months Ended July 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 348 $ — $ 7,166 $ (348 ) $ 7,166 Costs and expenses: Cost of products sold — 250 — 2,365 (354 ) 2,261 Research and development expense — 163 — 393 — 556 Selling, general, and administrative expense 3 280 — 2,145 — 2,428 Restructuring charges, net — 16 — 78 — 94 Certain litigation charges — — — 82 — 82 Acquisition-related items — 23 — 29 — 52 Amortization of intangible assets — 3 — 484 — 487 Other (income) expense, net 11 (640 ) — 668 — 39 Operating profit (loss) (14 ) 253 — 922 6 1,167 Interest income — (60 ) (156 ) (282 ) 405 (93 ) Interest expense 16 408 1 252 (405 ) 272 Interest expense (income), net 16 348 (155 ) (30 ) — 179 Equity in net (income) loss of subsidiaries (957 ) (1,246 ) (802 ) — 3,005 — Income from operations before income taxes 927 1,151 957 952 (2,999 ) 988 Provision (benefit) for income taxes (2 ) 22 — 39 — 59 Net income 929 1,129 957 913 (2,999 ) 929 Other comprehensive income (loss), net of tax (156 ) 95 (156 ) (172 ) 233 (156 ) Total comprehensive income $ 773 $ 1,224 $ 801 $ 741 $ (2,766 ) $ 773 Consolidating Statement of Comprehensive Income Three Months Ended July 31, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 373 $ — $ 7,274 $ (373 ) $ 7,274 Costs and expenses: Cost of products sold — 256 — 2,546 (346 ) 2,456 Research and development expense — 162 — 396 — 558 Selling, general, and administrative expense 2 249 — 2,198 — 2,449 Restructuring charges, net — 2 — 65 — 67 Acquisition-related items — 35 — 36 — 71 Amortization of intangible assets — 3 — 478 — 481 Other (income) expense, net 73 (388 ) — 376 — 61 Operating profit (loss) (75 ) 54 — 1,179 (27 ) 1,131 Interest income — (64 ) (183 ) (113 ) 245 (115 ) Interest expense 1 444 — 106 (245 ) 306 Interest expense (income), net 1 380 (183 ) (7 ) — 191 Equity in net (income) loss of subsidiaries (890 ) (911 ) (707 ) — 2,508 — Income from operations before income taxes 814 585 890 1,186 (2,535 ) 940 Provision (benefit) for income taxes (6 ) (162 ) — 288 — 120 Net income 820 747 890 898 (2,535 ) 820 Other comprehensive income (loss), net of tax (172 ) (153 ) (172 ) (219 ) 544 (172 ) Total comprehensive income $ 648 $ 594 $ 718 $ 679 $ (1,991 ) $ 648 Condensed Consolidating Balance Sheet July 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 46 $ 55 $ 2,959 $ — $ 3,060 Investments — — — 9,750 — 9,750 Accounts receivable, net — — — 5,357 — 5,357 Inventories — 153 — 3,621 (194 ) 3,580 Intercompany receivable 72 140,906 — 163,436 (304,414 ) — Other current assets 5 178 — 1,597 (29 ) 1,751 Total current assets 77 141,283 55 186,720 (304,637 ) 23,498 Property, plant, and equipment, net — 1,166 — 3,648 — 4,814 Goodwill — — — 41,309 — 41,309 Other intangible assets, net — 28 — 26,409 — 26,437 Tax assets — 699 — 533 — 1,232 Investment in subsidiaries 53,531 70,405 40,609 — (164,545 ) — Intercompany loans receivable 3,000 9,425 21,991 28,924 (63,340 ) — Other assets — 540 — 771 — 1,311 Total assets $ 56,608 $ 223,546 $ 62,655 $ 288,314 $ (532,522 ) $ 98,601 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 500 $ 975 $ 472 $ — $ 1,947 Accounts payable — 339 — 1,276 — 1,615 Intercompany payable — 152,269 — 152,145 (304,414 ) — Accrued compensation 67 362 — 776 — 1,205 Other accrued expenses 13 615 — 2,501 — 3,129 Total current liabilities 80 154,085 975 157,170 (304,414 ) 7,896 Long-term debt — 26,669 — 3,455 — 30,124 Accrued compensation and retirement benefits — 1,319 — 451 — 1,770 Accrued income taxes 10 1,522 — 812 — 2,344 Long-term intercompany loans payable 5,626 10,125 15,151 32,438 (63,340 ) — Deferred tax liabilities — — — 3,790 — 3,790 Other liabilities — 237 — 1,548 — 1,785 Total liabilities 5,716 193,957 16,126 199,664 (367,754 ) 47,709 Shareholders’ equity 50,892 29,589 46,529 88,582 (164,768 ) 50,824 Noncontrolling interests $ — $ — $ — $ 68 $ — $ 68 Total equity $ 50,892 $ 29,589 $ 46,529 $ 88,650 $ (164,768 ) $ 50,892 Total liabilities and equity $ 56,608 $ 223,546 $ 62,655 $ 288,314 $ (532,522 ) $ 98,601 Condensed Consolidating Balance Sheet April 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 55 $ — $ 2,821 $ — $ 2,876 Investments — — — 9,758 — 9,758 Accounts receivable, net — — — 5,562 — 5,562 Inventories — 162 — 3,511 (200 ) 3,473 Intercompany receivable 403 141,368 — 162,278 (304,049 ) — Other current assets 24 271 — 1,636 — 1,931 Total current assets 427 141,856 — 185,566 (304,249 ) 23,600 Property, plant, and equipment, net — 1,139 — 3,702 — 4,841 Goodwill — — — 41,500 — 41,500 Other intangible assets, net — 31 — 26,868 — 26,899 Tax assets — 690 — 693 — 1,383 Investment in subsidiaries 52,608 68,902 49,698 — (171,208 ) — Intercompany loans receivable 3,000 8,884 10,203 18,140 (40,227 ) — Other assets — 506 — 915 — 1,421 Total assets $ 56,035 $ 222,008 $ 59,901 $ 277,384 $ (515,684 ) $ 99,644 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 493 $ — $ 993 Accounts payable — 288 — 1,421 — 1,709 Intercompany payable — 151,687 — 152,362 (304,049 ) — Accrued compensation 32 616 — 1,064 — 1,712 Other accrued expenses 12 243 — 2,496 — 2,751 Total current liabilities 44 153,334 — 157,836 (304,049 ) 7,165 Long-term debt — 26,646 — 3,463 — 30,109 Accrued compensation and retirement benefits — 1,258 — 501 — 1,759 Accrued income taxes 10 1,422 — 1,471 — 2,903 Long-term intercompany loans payable 3,918 10,128 14,297 11,884 (40,227 ) — Deferred tax liabilities — — — 3,729 — 3,729 Other liabilities — 202 — 1,714 — 1,916 Total liabilities 3,972 192,990 14,297 180,598 (344,276 ) 47,581 Total shareholders' equity 52,063 29,018 45,604 96,786 (171,408 ) 52,063 Total liabilities and shareholders' equity $ 56,035 $ 222,008 $ 59,901 $ 277,384 $ (515,684 ) $ 99,644 Condensed Consolidating Statement of Cash Flows Three Months Ended July 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 440 $ 534 $ 13 $ 563 $ — $ 1,550 Investing Activities: Acquisitions, net of cash acquired — — — (12 ) — (12 ) Additions to property, plant, and equipment — — — (330 ) — (330 ) Purchases of investments — — — (1,206 ) 162 (1,044 ) Sales and maturities of investments — 162 — 1,104 (162 ) 1,104 Net (increase) decrease in intercompany loans — (541 ) (1,787 ) (785 ) 3,113 — Capital contribution paid — (162 ) — — 162 — Other investing activities, net — — — (2 ) — (2 ) Net cash provided by (used in) investing activities — (541 ) (1,787 ) (1,231 ) 3,275 (284 ) Financing Activities: Acquisition-related contingent consideration — — — (11 ) — (11 ) Change in current debt obligations, net — — 975 (49 ) — 926 Issuance of long-term debt — — — 33 — 33 Payments on long-term debt — — — (17 ) — (17 ) Dividends to shareholders (599 ) — — — — (599 ) Issuance of ordinary shares 214 — — — — 214 Repurchase of ordinary shares (1,763 ) — — — — (1,763 ) Net intercompany loan borrowings (repayments) 1,708 (2 ) 854 553 (3,113 ) — Capital contribution — — — 162 (162 ) — Other financing activities — — — 57 — 57 Net cash provided by (used in) financing activities (440 ) (2 ) 1,829 728 (3,275 ) (1,160 ) Effect of exchange rate changes on cash and cash equivalents — — — 78 — 78 Net change in cash and cash equivalents — (9 ) 55 138 — 184 Cash and cash equivalents at beginning of period — 55 — 2,821 — 2,876 Cash and cash equivalents at end of period $ — $ 46 $ 55 $ 2,959 $ — $ 3,060 Condensed Consolidating Statement of Cash Flows Three Months Ended July 31, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (2 ) $ (330 ) $ 178 $ 970 $ — $ 816 Investing Activities: Acquisitions, net of cash acquired — — — (179 ) — (179 ) Additions to property, plant, and equipment — (62 ) — (162 ) — (224 ) Purchases of investments — — — (1,851 ) — (1,851 ) Sales and maturities of investments — — — 1,266 — 1,266 Net (increase) decrease in intercompany loans (108 ) (99 ) (885 ) (135 ) 1,227 — Other investing activities, net — — — 2 — 2 Net cash provided by (used in) investing activities (108 ) (161 ) (885 ) (1,059 ) 1,227 (986 ) Financing Activities: Acquisition-related contingent consideration — — — (3 ) — (3 ) Change in current debt obligations, net — — 429 — — 429 Payments on long-term debt — — — (1,004 ) — (1,004 ) Dividends to shareholders (538 ) — — — — (538 ) Issuance of ordinary shares 98 — — — — 98 Repurchase of ordinary shares (750 ) — — — — (750 ) Net intercompany loan borrowings (repayments) 1,017 3 108 99 (1,227 ) — Other financing activities — — — 24 — 24 Net cash (used in) provided by financing activities (173 ) 3 537 (884 ) (1,227 ) (1,744 ) Effect of exchange rate changes on cash and cash equivalents — — — 50 — 50 Net change in cash and cash equivalents (283 ) (488 ) (170 ) (923 ) — (1,864 ) Cash and cash equivalents at beginning of period 263 1,071 170 3,339 — 4,843 Cash and cash equivalents at end of period $ (20 ) $ 583 $ — $ 2,416 $ — $ 2,979 Consolidating Statement of Comprehensive Income Three Months Ended July 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,166 $ — $ 7,166 Costs and expenses: Cost of products sold — — 2,261 — 2,261 Research and development expense — — — 556 — 556 Selling, general, and administrative expense 3 — — 2,425 — 2,428 Restructuring charges, net — — — 94 — 94 Certain litigation charges — — — 82 — 82 Acquisition-related items — — — 52 — 52 Amortization of intangible assets — — — 487 — 487 Other expense, net 11 1 — 27 — 39 Operating profit (loss) (14 ) (1 ) — 1,182 — 1,167 Interest income — (29 ) (157 ) (106 ) 199 (93 ) Interest expense 16 32 1 422 (199 ) 272 Interest expense (income), net 16 3 (156 ) 316 — 179 Equity in net (income) loss of subsidiaries (957 ) (805 ) (801 ) — 2,563 — Income from operations before income taxes 927 801 957 866 (2,563 ) 988 Provision (benefit) for income taxes (2 ) — — 61 — 59 Net income 929 801 957 805 (2,563 ) 929 Other comprehensive income (loss), net of tax (156 ) 42 (156 ) (156 ) 270 (156 ) Total comprehensive income $ 773 $ 843 $ 801 $ 649 $ (2,293 ) $ 773 Consolidating Statement of Comprehensive Income Three Months Ended July 31, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,274 $ — $ 7,274 Costs and expenses: Cost of products sold — — — 2,456 — 2,456 Research and development expense — — — 558 — 558 Selling, general, and administrative expense 2 — — 2,447 — 2,449 Restructuring charges, net — — — 67 — 67 Acquisition-related items — — — 71 — 71 Amortization of intangible assets — — — 481 — 481 Other (income) expense, net 73 — — (12 ) — 61 Operating profit (loss) (75 ) — — 1,206 — 1,131 Interest income — (164 ) (184 ) (118 ) 351 (115 ) Interest expense 1 36 1 619 (351 ) 306 Interest expense (income), net 1 (128 ) (183 ) 501 — 191 Equity in net (income) loss of subsidiaries (890 ) (77 ) (707 ) — 1,674 — Income from operations before income taxes 814 205 890 705 (1,674 ) 940 Provision (benefit) for income taxes (6 ) — — 126 — 120 Net income 820 205 890 579 (1,674 ) 820 Other comprehensive income (loss), net of tax (172 ) (66 ) (172 ) (172 ) 410 (172 ) Total comprehensive income 648 139 718 407 (1,264 ) 648 Condensed Consolidating Balance Sheet July 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 85 $ 55 $ 2,920 $ — $ 3,060 Investments — — — 9,750 — 9,750 Accounts receivable, net — — — 5,357 — 5,357 Inventories — — — 3,580 — 3,580 Intercompany receivable 72 — 60 — (132 ) — Other current assets 5 — — 1,746 — 1,751 Total current assets 77 85 115 23,353 (132 ) 23,498 Property, plant, and equipment, net — — — 4,814 — 4,814 Goodwill — — — 41,309 — 41,309 Other intangible assets, net — — — 26,437 — 26,437 Tax assets — — — 1,232 — 1,232 Investment in subsidiaries 53,531 21,282 39,285 — (114,098 ) — Intercompany loans receivable 3,000 3,963 23,256 17,885 (48,104 ) — Other assets — — — 1,311 — 1,311 Total assets $ 56,608 $ 25,330 $ 62,656 $ 116,341 $ (162,334 ) $ 98,601 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ — $ 975 $ 972 $ — $ 1,947 Accounts payable — — — 1,615 — 1,615 Intercompany payable — — — 132 (132 ) — Accrued compensation 67 — — 1,138 — 1,205 Other accrued expenses 13 35 — 3,081 — 3,129 Total current liabilities 80 35 975 6,938 (132 ) 7,896 Long-term debt — 3,363 — 26,761 — 30,124 Accrued compensation and retirement benefits — — — 1,770 — 1,770 Accrued income taxes 10 — — 2,334 — 2,344 Long-term intercompany loans payable 5,626 4,107 15,152 23,219 (48,104 ) — Deferred tax liabilities — — — 3,790 — 3,790 Other liabilities — — — 1,785 — 1,785 Total liabilities 5,716 7,505 16,127 66,597 (48,236 ) 47,709 Shareholders’ equity 50,892 17,825 46,529 49,676 (114,098 ) 50,824 Noncontrolling interests — — — 68 — 68 Total equity $ 50,892 $ 17,825 $ 46,529 $ 49,744 $ (114,098 ) $ 50,892 Total liabilities and equity $ 56,608 $ 25,330 $ 62,656 $ 116,341 $ (162,334 ) $ 98,601 Condensed Consolidating Balance Sheet April 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 208 $ — $ 2,668 $ — $ 2,876 Investments — — — 9,758 — 9,758 Accounts receivable, net — — — 5,562 — 5,562 Inventories — — — 3,473 — 3,473 Intercompany receivable 403 — 61 — (464 ) — Other current assets 24 — — 1,907 — 1,931 Total current assets 427 208 61 23,368 (464 ) 23,600 Property, plant, and equipment, net — — 1 4,840 — 4,841 Goodwill — — — 41,500 — 41,500 Other intangible assets, net — — — 26,899 — 26,899 Tax assets — — — 1,383 — 1,383 Investment in subsidiaries 52,608 36,477 48,375 — (137,460 ) — Intercompany loans receivable 3,000 8,253 11,465 27,724 (50,442 ) — Other assets — — — 1,421 — 1,421 Total assets $ 56,035 $ 44,938 $ 59,902 $ 127,135 $ (188,366 ) $ 99,644 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 993 $ — $ 993 Accounts payable — — — 1,709 — 1,709 Intercompany payable — — — 464 (464 ) — Accrued compensation 32 — — 1,680 — 1,712 Other accrued expenses 12 24 — 2,715 — 2,751 Total current liabilities 44 24 — 7,561 (464 ) 7,165 Long-term debt — 3,382 — 26,727 — 30,109 Accrued compensation and retirement benefits — — — 1,759 — 1,759 Accrued income taxes 10 — — 2,893 — 2,903 Long-term intercompany loans payable 3,918 14,689 14,298 17,537 (50,442 ) — Deferred tax liabilities — — — 3,729 — 3,729 Other liabilities — — — 1,916 — 1,916 Total liabilities 3,972 18,095 14,298 62,122 (50,906 ) 47,581 Total shareholders' equity 52,063 26,843 45,604 65,013 (137,460 ) 52,063 Total liabilities and shareholders' equity $ 56,035 $ 44,938 $ 59,902 $ 127,135 $ (188,366 ) $ 99,644 Condensed Consolidating Statement of Cash Flows Three Months Ended July 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 440 $ (7 ) $ — $ 1,117 $ — $ 1,550 Investing Activities: Acquisitions, net of cash acquired — — — (12 ) — (12 ) Additions to property, plant, and equipment — — — (330 ) — (330 ) Purchases of investments — — — (1,044 ) — (1,044 ) Sales and maturities of investments — — — 1,104 — 1,104 Net (increase) decrease in intercompany loans receivable — 4,290 (1,774 ) 3,334 (5,850 ) — Capital contributions paid — (325 ) — — 325 — Other investing activities, net — — — (2 ) — (2 ) Net cash provided by (used in) investing activities — 3,965 (1,774 ) 3,050 (5,525 ) (284 ) Financing Activities: Acquisition-related contingent consideration — — — (11 ) — (11 ) Change in current debt obligations, net — — 975 (49 ) — 926 Issuance of long-term debt — — — 33 — 33 Payments on long-term debt — — — (17 ) — (17 ) Dividends to shareholders (599 ) — — — — (599 ) Issuance of ordinary shares 214 — — — — 214 Repurchase of ordinary shares (1,763 ) — — — — (1,763 ) Net intercompany loan borrowings (repayments) 1,708 (4,081 ) 854 (4,331 ) 5,850 — Intercompany dividend paid — — — — — — Capital contributions received — — — 325 (325 ) — Other financing activities — — — 57 — 57 Net cash provided by (used in) financing activities (440 ) (4,081 ) 1,829 (3,993 ) 5,525 (1,160 ) Effect of exchange rate changes on cash and cash equivalents — — — 78 — 78 Net change in cash and cash equivalents — (123 ) 55 252 — 184 Cash and cash equivalents at beginning of period — 208 — 2,668 — 2,876 Cash and cash equivalents at end of period $ — $ 85 $ 55 $ 2,920 $ — $ 3,060 Condensed Consolidating Statement of Cash Flows Three Months Ended July 31, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (2 ) $ 468 $ 374 $ 476 $ (500 ) $ 816 Investing Activities: Acquisitions, net of cash acquired — — — (179 ) — (179 ) Additions to property, plant, and equipment — — — (224 ) — (224 ) Purchases of investments — — — (1,851 ) — (1,851 ) Sales and maturities of investments — — — 1,266 — 1,266 Net (increase) decrease in intercompany loans receivable (108 ) (195 ) (1,081 ) (3,628 ) 5,012 — Other investing activities, net — — — 2 — 2 Net cash provided by (used in) investing activities (108 ) (195 ) (1,081 ) (4,614 ) 5,012 (986 ) Financing Activities: Acquisition-related contingent consideration — — — (3 ) — (3 ) Change in current debt obligations, net — — 429 — — 429 Issuance of long-term debt — — — — — — Payments on long-term debt — (1,000 ) — (4 ) — (1,004 ) Dividends to shareholders (538 ) — — — — (538 ) Issuance of ordinary shares 98 — — — — 98 Repurchase of ordinary shares (750 ) — — — — (750 ) Net intercompany loan borrowings (repayments) 1,017 179 108 3,708 (5,012 ) — Intercompany dividend paid — — — (500 ) 500 — Other financing activities — — — 24 — 24 Net cash provided by (used in) financing activities (173 ) (821 ) 537 3,225 (4,512 ) (1,744 ) Effect of exchange rate changes on cash and cash equivalents — — — 50 — 50 Net change in cash and cash equivalents (283 ) (548 ) (170 ) (863 ) — (1,864 ) Cash and cash equivalents at beginning of period 263 728 170 3,682 — 4,843 Cash and cash equivalents at end of period $ (20 ) $ 180 $ — $ 2,819 $ — $ 2,979

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Jul. 29, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic or the Company) for the periods presented. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 29, 2016 .
Consolidation	The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.
Fiscal Period	The Company’s fiscal years 2017 , 2016 , and 2015 will end or ended on April 28, 2017 , April 29, 2016 , and April 24, 2015 , respectively.
New Accounting Pronouncements	Recently Adopted In April 2015, the Financial Accounting Standards Board (FASB) issued accounting guidance that requires debt issuance costs to be presented in the balance sheet as a direct deduction from the related debt liability. Prior to this amendment, debt issuance costs were recognized as an asset in the balance sheet and did not offset the related debt liability. The Company retrospectively adopted this guidance in the first quarter of fiscal year 2017. Its adoption had an impact of $133 million and $138 million on the Company's consolidated balance sheets at July 29, 2016 and April 29, 2016 , respectively. Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s consolidated financial statements. In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is evaluating the impact of the equity investment guidance on the Company's consolidated financial statements. In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements. In March 2016, the FASB issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefit and deficiencies as additional paid-in capital. For the three months ended July 29, 2016, the Company recognized $57 million of excess tax benefits in additional paid-in capital. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018.

Acquisitions and Acquisition-26

Acquisitions and Acquisition-Related Items (Tables)	3 Months Ended
	Jul. 29, 2016
Business Acquisition [Line Items]
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at (in millions) July 29, 2016 Valuation Technique Unobservable Input Range Discount rate 11% - 32.5% Revenue-based payments $194 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2017 - 2025 Discount rate 0.3% - 5.5% Product development-based payments $185 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2017 - 2025
Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended (in millions) July 29, 2016 July 31, 2015 Beginning Balance $ 377 $ 264 Purchase price contingent consideration 21 26 Payments (14 ) (3 ) Change in fair value (5 ) 4 Ending Balance $ 379 $ 291
2017 Acquisitions [Member]
Business Acquisition [Line Items]
Fair Value of Assets Acquired and Liabilities Assumed	The fair values of the assets acquired and liabilities assumed during the three months ended July 29, 2016 were as follows: (in millions) Other current assets $ 8 Property, plant, and equipment 5 Other intangible assets 48 Goodwill 56 Total assets acquired 117 Current liabilities 3 Deferred tax liabilities 3 Other liabilities 3 Total liabilities assumed 9 Net assets acquired $ 108

Restructuring Charges, Net (Tab

Restructuring Charges, Net (Tables)	3 Months Ended
	Jul. 29, 2016
Cost Synergies Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	A summary of the restructuring accrual, recorded within other accrued expenses and other liabilities in the consolidated balance sheets, and related activity is presented below: (in millions) Employee Termination Costs Asset Write-downs Other Costs Total April 29, 2016 $ 213 $ — $ 37 $ 250 Restructuring charges 77 14 20 111 Payments/write-downs (68 ) (14 ) (16 ) (98 ) Reversal of excess accrual (8 ) — 1 (7 ) July 29, 2016 $ 214 $ — $ 42 $ 256

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Jul. 29, 2016
Investments [Abstract]
Investments by Category and Related Balance Sheet Classification	The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at July 29, 2016 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 675 $ 28 $ — $ 703 $ 703 $ — Marketable equity securities 85 45 (1 ) 129 — 129 Total Level 1 760 73 (1 ) 832 703 129 Level 2: Corporate debt securities 4,113 123 (14 ) 4,222 4,222 — U.S. government and agency securities 914 3 — 917 917 — Mortgage-backed securities 917 26 (16 ) 927 927 — Foreign government and agency securities 15 — — 15 15 — Other asset-backed securities 230 3 — 233 233 — Debt funds 2,872 14 (246 ) 2,640 2,640 — Total Level 2 9,061 169 (276 ) 8,954 8,954 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Total available-for-sale securities $ 9,869 $ 242 $ (280 ) $ 9,831 $ 9,657 $ 174 Trading securities: Level 1: Exchange-traded funds 75 19 (1 ) 93 93 — Total Level 1 75 19 (1 ) 93 93 — Total trading securities $ 75 $ 19 $ (1 ) $ 93 $ 93 $ — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 546 — — N/A — 546 Total Level 3 546 — — N/A — 546 Total cost method, equity method, and other investments $ 546 $ — $ — N/A $ — $ 546 Total investments $ 10,490 $ 261 $ (281 ) $ 9,924 $ 9,750 $ 720 The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 29, 2016 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 792 $ 14 $ (1 ) $ 805 $ 805 $ — Marketable equity securities 75 21 (11 ) 85 — 85 Total Level 1 867 35 (12 ) 890 805 85 Level 2: Corporate debt securities 3,935 85 (24 ) 3,996 3,996 — U.S. government and agency securities 902 2 — 904 904 — Mortgage-backed securities 1,016 17 (18 ) 1,015 1,015 — Other asset-backed securities 192 3 — 195 195 — Debt funds 3,040 5 (281 ) 2,764 2,764 — Total Level 2 9,085 112 (323 ) 8,874 8,874 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Total available-for-sale securities $ 10,000 $ 147 $ (338 ) $ 9,809 $ 9,679 $ 130 Trading securities: Level 1: Exchange-traded funds 65 15 (1 ) 79 79 — Total Level 1 65 15 (1 ) 79 79 — Total trading securities $ 65 $ 15 $ (1 ) $ 79 $ 79 $ — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 506 — — N/A — 506 Total Level 3 506 — — N/A — 506 Total cost method, equity method, and other investments $ 506 $ — $ — N/A $ — $ 506 Total investments $ 10,571 $ 162 $ (339 ) $ 9,888 $ 9,758 $ 636
Gross Unrealized Losses and Fair Values of Available-for-sale Securities that Have Been in a Continuous Unrealized Loss Position Deemed to be Temporary, Aggregated by Investment Category	The following tables represents the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at July 29, 2016 and April 29, 2016 : July 29, 2016 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 494 $ (6 ) $ 216 $ (8 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 208 (6 ) 121 (10 ) Debt funds 851 — 1,789 (246 ) Marketable equity securities $ 4 $ (1 ) $ — $ — Total $ 1,557 $ (13 ) $ 2,170 $ (267 ) April 29, 2016 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 756 $ (18 ) $ 136 $ (6 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 196 (5 ) 92 (5 ) U.S. government and agency securities 308 (4 ) 67 (5 ) Debt funds 670 (26 ) 1,601 (256 ) Marketable equity securities 45 (11 ) — — Total $ 1,975 $ (64 ) $ 1,940 $ (275 )
Unobservable Inputs Utilized in the Fair Value Measurement of Auction Rate Securities Classified as Level 3	The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at July 29, 2016 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6%
Reconciliation of Beginning and Ending Balances of Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3)	The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): (in millions) Total Level 3 Corporate Debt Auction Rate April 29, 2016 $ 45 $ 1 $ 44 Total unrealized losses included in other comprehensive income — — — July 29, 2016 $ 45 $ 1 $ 44 (in millions) Total Level 3 Corporate Debt Auction Rate April 24, 2015 $ 106 $ 1 $ 105 Total unrealized losses included in other comprehensive income (3 ) — (3 ) July 31, 2015 $ 103 $ 1 $ 102
Activity Related to the Company's Investment Portfolio	Activity related to the Company’s investment portfolio is as follows: Three months ended July 29, 2016 July 31, 2015 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 1,098 $ 6 $ 1,237 $ 29 Gross realized gains 7 4 5 12 Gross realized losses (12 ) — (5 ) — Impairment losses recognized — (3 ) — (23 ) (1) Includes available-for-sale debt securities. (2) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments.
Available-for-sale Debt Securities Contractual Maturities	The July 29, 2016 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) July 29, 2016 Due in one year or less $ 969 Due after one year through five years 3,188 Due after five years through ten years 2,845 Due after ten years 60 Total $ 7,062

Financing Arrangements (Tables)

Financing Arrangements (Tables)	3 Months Ended
	Jul. 29, 2016
Debt Disclosure [Abstract]
Long-term Debt	Long-term debt consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year July 29, 2016 April 29, 2016 6.000 percent ten-year 2008 CIFSA senior notes 2018 $ 1,150 $ 1,150 1.500 percent three-year 2015 senior notes 2018 1,000 1,000 1.375 percent five-year 2013 senior notes 2018 1,000 1,000 5.600 percent ten-year 2009 senior notes 2019 400 400 4.450 percent ten-year 2010 senior notes 2020 766 766 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 530 530 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 4.375 percent twenty-year 2015 senior notes 2035 2,382 2,382 6.550 percent thirty-year 2008 CIFSA senior notes 2038 374 374 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 325 325 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,000 4,000 Three-year term loan 2018 3,000 3,000 Interest rate swaps (Note 7) 2018 - 2022 106 89 Capital lease obligations 2018 - 2025 25 26 Bank borrowings 2021 66 56 Debt premium 2018 - 2045 198 214 Deferred Financing Costs (1) 2018-2045 (133 ) (138 ) Total Long-Term Debt $ 30,124 $ 30,109 (1) We retrospectively adopted the guidance to simplify the presentation of deferred issuance costs in the quarter ending July 29, 2016. As a result deferred issuance costs have been reclassified from other assets to long-term debt. See Note 2 to the consolidated financial statements for additional information.

Derivatives and Foreign Excha30

Derivatives and Foreign Exchange Risk Management (Tables)	3 Months Ended
	Jul. 29, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amounts and classification of the (losses) gains in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three months ended July 29, 2016 and July 31, 2015 were as follows: (in millions) Three months ended Derivatives Not Designated as Hedging Instruments Classification July 29, 2016 July 31, 2015 Currency exchange rate contracts (losses) gains Other expense, net $ (3 ) $ 20
Amount and Location of Gains (Losses) in Statements of Income and OCI, Derivative Instruments Designated as Cash Flow Hedges	The amount of gains (losses) and location of the gains (losses) in the consolidated statements of income and other comprehensive (loss) income (OCI) related to currency exchange rate contract derivative instruments designated as cash flow hedges for the three months ended July 29, 2016 and July 31, 2015 were as follows: Three months ended July 29, 2016 Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income (in millions) Derivatives in Cash Flow Hedging Relationships Amount Classification Amount Currency exchange rate contracts $ 121 Other expense, net $ 15 Three months ended July 31, 2015 Gross Gains (Losses) Recognized in OCI Effective Portion of Gains (Losses) on Derivative Reclassified from (in millions) Derivatives in Cash Flow Hedging Relationships Amount Classification Amount Currency exchange rate contracts $ (14 ) Other expense, net $ 95 Cost of products sold (21 ) Total $ (14 ) $ 74
Location and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the balance sheet classification and fair value amounts of derivative instruments reported in the consolidated balance sheets at July 29, 2016 and April 29, 2016 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories. July 29, 2016 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets 191 Other accrued expenses 101 Interest rate contracts Other assets 106 Other liabilities 71 Currency exchange rate contracts Other assets 55 Other liabilities 55 Total derivatives designated as hedging instruments $ 352 $ 227 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets $ 26 Other accrued expenses $ 13 Cross currency interest rate contracts Other assets 10 Other liabilities 10 Total derivatives not designated as hedging instruments $ 36 $ 23 Total derivatives $ 388 $ 250 April 29, 2016 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 123 Other accrued expenses $ 89 Interest rate contracts Other assets 89 Other liabilities 48 Currency exchange rate contracts Other assets 9 Other liabilities 54 Total derivatives designated as hedging instruments $ 221 $ 191 Derivatives not designated as hedging instruments Commodity derivatives Other current assets $ — Other accrued expenses $ 1 Currency exchange rate contracts Other current assets 13 Other accrued expenses 23 Cross currency interest rate contracts Other assets 14 Other liabilities 4 Total derivatives not designated as hedging instruments $ 27 $ 28 Total derivatives $ 248 $ 219
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis at July 29, 2016 and April 29, 2016 . July 29, 2016 April 29, 2016 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 272 $ 116 $ 145 $ 103 Derivative liabilities 169 81 166 53
Offsetting Assets	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. July 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative Assets Currency exchange rate contracts $ 272 $ (189 ) $ — $ 83 Interest rate contracts 106 (20 ) — 86 Cross currency interest rate contracts 10 (5 ) — 5 $ 388 $ (214 ) $ — $ 174 Derivative Liabilities Currency exchange rate contracts $ (169 ) $ 146 $ — $ (23 ) Interest rate contracts (71 ) 63 — (8 ) Cross currency interest rate contracts (10 ) 5 — (5 ) $ (250 ) $ 214 $ — $ (36 ) Total $ 138 $ — $ — $ 138 April 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative Assets Currency exchange rate contracts $ 145 $ (98 ) $ (1 ) $ 46 Interest rate contracts 89 (20 ) — 69 Cross currency interest rate contracts 14 — — 14 $ 248 $ (118 ) $ (1 ) $ 129 Derivative Liabilities Currency exchange rate contracts $ (166 ) $ 85 $ 26 $ (55 ) Interest rate contracts (48 ) 34 — (14 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity contracts (1 ) — — (1 ) $ (219 ) $ 119 $ 26 $ (74 ) Total $ 29 $ 1 $ 25 $ 55
Offsetting Liabilities	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. July 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative Assets Currency exchange rate contracts $ 272 $ (189 ) $ — $ 83 Interest rate contracts 106 (20 ) — 86 Cross currency interest rate contracts 10 (5 ) — 5 $ 388 $ (214 ) $ — $ 174 Derivative Liabilities Currency exchange rate contracts $ (169 ) $ 146 $ — $ (23 ) Interest rate contracts (71 ) 63 — (8 ) Cross currency interest rate contracts (10 ) 5 — (5 ) $ (250 ) $ 214 $ — $ (36 ) Total $ 138 $ — $ — $ 138 April 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recognized Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative Assets Currency exchange rate contracts $ 145 $ (98 ) $ (1 ) $ 46 Interest rate contracts 89 (20 ) — 69 Cross currency interest rate contracts 14 — — 14 $ 248 $ (118 ) $ (1 ) $ 129 Derivative Liabilities Currency exchange rate contracts $ (166 ) $ 85 $ 26 $ (55 ) Interest rate contracts (48 ) 34 — (14 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity contracts (1 ) — — (1 ) $ (219 ) $ 119 $ 26 $ (74 ) Total $ 29 $ 1 $ 25 $ 55

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Jul. 29, 2016
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances were as follows: (in millions) July 29, 2016 April 29, 2016 Finished goods $ 2,346 $ 2,242 Work in-process 497 499 Raw materials 737 732 Total $ 3,580 $ 3,473

Goodwill and Other Intangible32

Goodwill and Other Intangible Assets, Net (Tables)	3 Months Ended
	Jul. 29, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill by reporting unit for the three months ended July 29, 2016 were as follows: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 29, 2016 $ 6,243 $ 23,784 $ 9,620 $ 1,853 $ 41,500 Goodwill as a result of acquisitions 27 (3 ) 32 — 56 Currency adjustment, net (11 ) (231 ) (5 ) — (247 ) July 29, 2016 $ 6,259 $ 23,550 $ 9,647 $ 1,853 $ 41,309
Gross Carrying Amount of Non-Amortizable Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at July 29, 2016 and April 29, 2016 were as follows: July 29, 2016 April 29, 2016 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 18,614 $ (1,596 ) $ 18,596 $ (1,331 ) Purchased technology and patents 11,537 (3,173 ) 11,397 (2,976 ) Trademarks and tradenames 804 (425 ) 854 (403 ) Other 72 (34 ) 72 (31 ) Total $ 31,027 $ (5,228 ) $ 30,919 $ (4,741 ) Indefinite-lived: IPR&D $ 638 $ 721
Gross Carrying Amount and Accumulated Amortization of Amortizable Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at July 29, 2016 and April 29, 2016 were as follows: July 29, 2016 April 29, 2016 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 18,614 $ (1,596 ) $ 18,596 $ (1,331 ) Purchased technology and patents 11,537 (3,173 ) 11,397 (2,976 ) Trademarks and tradenames 804 (425 ) 854 (403 ) Other 72 (34 ) 72 (31 ) Total $ 31,027 $ (5,228 ) $ 30,919 $ (4,741 ) Indefinite-lived: IPR&D $ 638 $ 721
Estimated Future Aggregate Amortization Expense, Amortizable Intangible Assets	Estimated aggregate amortization expense by fiscal year based on the current carrying value of definite-lived intangible assets at July 29, 2016 , excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2017 $ 1,449 2018 1,905 2019 1,811 2020 1,763 2021 1,746 2022 1,705

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Jul. 29, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings per share: Three months ended (in millions, except per share data) July 29, 2016 July 31, 2015 Numerator: Net income attributable to ordinary shareholders $ 929 $ 820 Denominator: Basic – weighted average shares outstanding 1,392.2 1,418.1 Effect of dilutive securities: Employee stock options 10.5 13.2 Employee restricted stock units 3.9 5.0 Other 0.5 0.1 Diluted – weighted average shares outstanding 1,407.1 1,436.4 Basic earnings per share $ 0.67 $ 0.58 Diluted earnings per share $ 0.66 $ 0.57

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Jul. 29, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock awards, and employee stock purchase plan shares recognized for the three months ended July 29, 2016 and July 31, 2015 : Three months ended (in millions) July 29, 2016 July 31, 2015 Stock options $ 38 $ 57 Restricted stock awards 34 34 Employee stock purchase plan shares 7 5 Total stock-based compensation expense $ 79 $ 96 Cost of products sold $ 11 $ 12 Research and development expense 9 8 Selling, general, and administrative expense 51 49 Restructuring charges, net 1 8 Acquisition-related items 7 19 Total stock-based compensation expense $ 79 $ 96 Income tax benefits (21 ) (29 ) Total stock-based compensation expense, net of tax $ 58 $ 67

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	3 Months Ended
	Jul. 29, 2016
Compensation and Retirement Disclosure [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three months ended July 29, 2016 and July 31, 2015 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) July 29, 2016 July 31, 2015 July 29, 2016 July 31, 2015 Service cost $ 29 $ 30 $ 19 $ 22 Interest cost 27 31 6 9 Expected return on plan assets (47 ) (45 ) (12 ) (13 ) Amortization of net actuarial loss 23 24 4 6 Net periodic benefit cost $ 32 $ 40 $ 17 $ 24

Accumulated Other Comprehensi36

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure (Tables)	3 Months Ended
	Jul. 29, 2016
Equity [Abstract]
Changes in AOCI by Component	Changes in AOCI by component are as follows: (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities (1) Cumulative Translation Adjustments (2) Net Change in Retirement Obligations (3) Unrealized Gain (Loss) on Derivatives (4) Total Accumulated Other Comprehensive (Loss) Income April 29, 2016, net of tax $ (107 ) $ (474 ) $ (1,197 ) $ (90 ) $ (1,868 ) Other comprehensive income (loss) before reclassifications, before tax 168 (350 ) — 98 (84 ) Tax expense (52 ) — — (36 ) (88 ) Other comprehensive income (loss) before reclassifications, net of tax 116 (350 ) — 62 (172 ) Reclassifications, before tax (1 ) — 27 (14 ) 12 Tax (expense) benefit — — (2 ) 6 4 Reclassifications, net of tax (1 ) — 25 (8 ) 16 Other comprehensive income (loss), net of tax 115 (350 ) 25 54 (156 ) July 29, 2016, net of tax $ 8 $ (824 ) $ (1,172 ) $ (36 ) $ (2,024 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities (1) Cumulative Translation Adjustments (2) Net Change in Retirement Obligations (3) Unrealized Gain (Loss) on Derivatives (4) Total Accumulated Other Comprehensive (Loss) Income April 24, 2015, net of tax $ 14 $ (277 ) $ (1,131 ) $ 210 $ (1,184 ) Other comprehensive (loss) income before reclassifications, before tax (193 ) (26 ) (7 ) 14 (212 ) Tax benefit (expense) 70 — — (6 ) 64 Other comprehensive (loss) income before reclassifications, net of tax (123 ) (26 ) (7 ) 8 (148 ) Reclassifications, before tax (12 ) — 30 (62 ) (44 ) Tax benefit (expense) 4 — (10 ) 26 20 Reclassifications, net of tax (8 ) — 20 (36 ) (24 ) Other comprehensive (loss) income, net of tax (131 ) (26 ) 13 (28 ) (172 ) July 31, 2015, net of tax $ (117 ) $ (303 ) $ (1,118 ) $ 182 $ (1,356 ) (1) Represents net realized gains (losses) on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 5 ). (2) Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. (3) Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 13 ). (4) Relates to currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 7 ).
Supplemental Equity Schedule	The supplemental equity schedule below presents changes in the Company's noncontrolling interests and total shareholders' equity for the three months ended July 29, 2016 . (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 29, 2016 $ 52,063 $ — $ 52,063 Net income 929 — 929 Other comprehensive loss (156 ) — (156 ) Dividends to shareholders (599 ) — (599 ) Issuance of shares under stock purchase and award plans 214 — 214 Repurchase of ordinary shares (1,763 ) — (1,763 ) Tax benefit from exercise of stock-based awards 57 — 57 Stock-based compensation 79 — 79 Additions of noncontrolling ownership interests — 68 68 July 29, 2016 $ 50,824 $ 68 $ 50,892

Segment and Geographic Inform37

Segment and Geographic Information (Tables)	3 Months Ended
	Jul. 29, 2016
Segment Reporting [Abstract]
Net Sales by Segment	Net sales and income from operations before income taxes by reportable segment are as follows: Three months ended (in millions) July 29, 2016 July 31, 2015 Cardiac and Vascular Group $ 2,518 $ 2,567 Minimally Invasive Therapies Group 2,424 2,456 Restorative Therapies Group 1,772 1,806 Diabetes Group 452 445 Total net sales $ 7,166 $ 7,274
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Three months ended (in millions) July 29, 2016 July 31, 2015 Cardiac and Vascular Group $ 656 $ 817 Minimally Invasive Therapies Group 283 334 Restorative Therapies Group 507 481 Diabetes Group 112 117 Total reportable segments’ income from operations before income taxes 1,558 1,749 Impact of inventory step-up — (226 ) Restructuring charges, net (104 ) (67 ) Certain litigation charges (82 ) — Acquisition-related items (52 ) (71 ) Interest expense, net (179 ) (191 ) Corporate (153 ) (254 ) Total income from operations before income taxes $ 988 $ 940
Net Sales to External Customers by Geography	Net sales to external customers by geography are as follows: Three months ended (in millions) July 29, 2016 July 31, 2015 Americas (1) $ 4,297 $ 4,445 EMEA (2) 1,650 1,669 Asia-Pacific 822 770 Greater China 397 390 Total net sales $ 7,166 $ 7,274 (1) The U.S., which is included in the Americas, had net sales to external customers of $4.0 billion for the three months ended July 29, 2016 , and of $4.1 billion for the three months ended July 31, 2015 . (2) EMEA consists of the following regions: Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

Guarantor Financial Informati38

Guarantor Financial Information (Tables)	3 Months Ended
	Jul. 29, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Consolidating Statement of Comprehensive Income	Consolidating Statement of Comprehensive Income Three Months Ended July 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 348 $ — $ 7,166 $ (348 ) $ 7,166 Costs and expenses: Cost of products sold — 250 — 2,365 (354 ) 2,261 Research and development expense — 163 — 393 — 556 Selling, general, and administrative expense 3 280 — 2,145 — 2,428 Restructuring charges, net — 16 — 78 — 94 Certain litigation charges — — — 82 — 82 Acquisition-related items — 23 — 29 — 52 Amortization of intangible assets — 3 — 484 — 487 Other (income) expense, net 11 (640 ) — 668 — 39 Operating profit (loss) (14 ) 253 — 922 6 1,167 Interest income — (60 ) (156 ) (282 ) 405 (93 ) Interest expense 16 408 1 252 (405 ) 272 Interest expense (income), net 16 348 (155 ) (30 ) — 179 Equity in net (income) loss of subsidiaries (957 ) (1,246 ) (802 ) — 3,005 — Income from operations before income taxes 927 1,151 957 952 (2,999 ) 988 Provision (benefit) for income taxes (2 ) 22 — 39 — 59 Net income 929 1,129 957 913 (2,999 ) 929 Other comprehensive income (loss), net of tax (156 ) 95 (156 ) (172 ) 233 (156 ) Total comprehensive income $ 773 $ 1,224 $ 801 $ 741 $ (2,766 ) $ 773 Consolidating Statement of Comprehensive Income Three Months Ended July 31, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 373 $ — $ 7,274 $ (373 ) $ 7,274 Costs and expenses: Cost of products sold — 256 — 2,546 (346 ) 2,456 Research and development expense — 162 — 396 — 558 Selling, general, and administrative expense 2 249 — 2,198 — 2,449 Restructuring charges, net — 2 — 65 — 67 Acquisition-related items — 35 — 36 — 71 Amortization of intangible assets — 3 — 478 — 481 Other (income) expense, net 73 (388 ) — 376 — 61 Operating profit (loss) (75 ) 54 — 1,179 (27 ) 1,131 Interest income — (64 ) (183 ) (113 ) 245 (115 ) Interest expense 1 444 — 106 (245 ) 306 Interest expense (income), net 1 380 (183 ) (7 ) — 191 Equity in net (income) loss of subsidiaries (890 ) (911 ) (707 ) — 2,508 — Income from operations before income taxes 814 585 890 1,186 (2,535 ) 940 Provision (benefit) for income taxes (6 ) (162 ) — 288 — 120 Net income 820 747 890 898 (2,535 ) 820 Other comprehensive income (loss), net of tax (172 ) (153 ) (172 ) (219 ) 544 (172 ) Total comprehensive income $ 648 $ 594 $ 718 $ 679 $ (1,991 ) $ 648 Consolidating Statement of Comprehensive Income Three Months Ended July 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,166 $ — $ 7,166 Costs and expenses: Cost of products sold — — 2,261 — 2,261 Research and development expense — — — 556 — 556 Selling, general, and administrative expense 3 — — 2,425 — 2,428 Restructuring charges, net — — — 94 — 94 Certain litigation charges — — — 82 — 82 Acquisition-related items — — — 52 — 52 Amortization of intangible assets — — — 487 — 487 Other expense, net 11 1 — 27 — 39 Operating profit (loss) (14 ) (1 ) — 1,182 — 1,167 Interest income — (29 ) (157 ) (106 ) 199 (93 ) Interest expense 16 32 1 422 (199 ) 272 Interest expense (income), net 16 3 (156 ) 316 — 179 Equity in net (income) loss of subsidiaries (957 ) (805 ) (801 ) — 2,563 — Income from operations before income taxes 927 801 957 866 (2,563 ) 988 Provision (benefit) for income taxes (2 ) — — 61 — 59 Net income 929 801 957 805 (2,563 ) 929 Other comprehensive income (loss), net of tax (156 ) 42 (156 ) (156 ) 270 (156 ) Total comprehensive income $ 773 $ 843 $ 801 $ 649 $ (2,293 ) $ 773 Consolidating Statement of Comprehensive Income Three Months Ended July 31, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,274 $ — $ 7,274 Costs and expenses: Cost of products sold — — — 2,456 — 2,456 Research and development expense — — — 558 — 558 Selling, general, and administrative expense 2 — — 2,447 — 2,449 Restructuring charges, net — — — 67 — 67 Acquisition-related items — — — 71 — 71 Amortization of intangible assets — — — 481 — 481 Other (income) expense, net 73 — — (12 ) — 61 Operating profit (loss) (75 ) — — 1,206 — 1,131 Interest income — (164 ) (184 ) (118 ) 351 (115 ) Interest expense 1 36 1 619 (351 ) 306 Interest expense (income), net 1 (128 ) (183 ) 501 — 191 Equity in net (income) loss of subsidiaries (890 ) (77 ) (707 ) — 1,674 — Income from operations before income taxes 814 205 890 705 (1,674 ) 940 Provision (benefit) for income taxes (6 ) — — 126 — 120 Net income 820 205 890 579 (1,674 ) 820 Other comprehensive income (loss), net of tax (172 ) (66 ) (172 ) (172 ) 410 (172 ) Total comprehensive income 648 139 718 407 (1,264 ) 648
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet July 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 46 $ 55 $ 2,959 $ — $ 3,060 Investments — — — 9,750 — 9,750 Accounts receivable, net — — — 5,357 — 5,357 Inventories — 153 — 3,621 (194 ) 3,580 Intercompany receivable 72 140,906 — 163,436 (304,414 ) — Other current assets 5 178 — 1,597 (29 ) 1,751 Total current assets 77 141,283 55 186,720 (304,637 ) 23,498 Property, plant, and equipment, net — 1,166 — 3,648 — 4,814 Goodwill — — — 41,309 — 41,309 Other intangible assets, net — 28 — 26,409 — 26,437 Tax assets — 699 — 533 — 1,232 Investment in subsidiaries 53,531 70,405 40,609 — (164,545 ) — Intercompany loans receivable 3,000 9,425 21,991 28,924 (63,340 ) — Other assets — 540 — 771 — 1,311 Total assets $ 56,608 $ 223,546 $ 62,655 $ 288,314 $ (532,522 ) $ 98,601 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 500 $ 975 $ 472 $ — $ 1,947 Accounts payable — 339 — 1,276 — 1,615 Intercompany payable — 152,269 — 152,145 (304,414 ) — Accrued compensation 67 362 — 776 — 1,205 Other accrued expenses 13 615 — 2,501 — 3,129 Total current liabilities 80 154,085 975 157,170 (304,414 ) 7,896 Long-term debt — 26,669 — 3,455 — 30,124 Accrued compensation and retirement benefits — 1,319 — 451 — 1,770 Accrued income taxes 10 1,522 — 812 — 2,344 Long-term intercompany loans payable 5,626 10,125 15,151 32,438 (63,340 ) — Deferred tax liabilities — — — 3,790 — 3,790 Other liabilities — 237 — 1,548 — 1,785 Total liabilities 5,716 193,957 16,126 199,664 (367,754 ) 47,709 Shareholders’ equity 50,892 29,589 46,529 88,582 (164,768 ) 50,824 Noncontrolling interests $ — $ — $ — $ 68 $ — $ 68 Total equity $ 50,892 $ 29,589 $ 46,529 $ 88,650 $ (164,768 ) $ 50,892 Total liabilities and equity $ 56,608 $ 223,546 $ 62,655 $ 288,314 $ (532,522 ) $ 98,601 Condensed Consolidating Balance Sheet April 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 55 $ — $ 2,821 $ — $ 2,876 Investments — — — 9,758 — 9,758 Accounts receivable, net — — — 5,562 — 5,562 Inventories — 162 — 3,511 (200 ) 3,473 Intercompany receivable 403 141,368 — 162,278 (304,049 ) — Other current assets 24 271 — 1,636 — 1,931 Total current assets 427 141,856 — 185,566 (304,249 ) 23,600 Property, plant, and equipment, net — 1,139 — 3,702 — 4,841 Goodwill — — — 41,500 — 41,500 Other intangible assets, net — 31 — 26,868 — 26,899 Tax assets — 690 — 693 — 1,383 Investment in subsidiaries 52,608 68,902 49,698 — (171,208 ) — Intercompany loans receivable 3,000 8,884 10,203 18,140 (40,227 ) — Other assets — 506 — 915 — 1,421 Total assets $ 56,035 $ 222,008 $ 59,901 $ 277,384 $ (515,684 ) $ 99,644 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 493 $ — $ 993 Accounts payable — 288 — 1,421 — 1,709 Intercompany payable — 151,687 — 152,362 (304,049 ) — Accrued compensation 32 616 — 1,064 — 1,712 Other accrued expenses 12 243 — 2,496 — 2,751 Total current liabilities 44 153,334 — 157,836 (304,049 ) 7,165 Long-term debt — 26,646 — 3,463 — 30,109 Accrued compensation and retirement benefits — 1,258 — 501 — 1,759 Accrued income taxes 10 1,422 — 1,471 — 2,903 Long-term intercompany loans payable 3,918 10,128 14,297 11,884 (40,227 ) — Deferred tax liabilities — — — 3,729 — 3,729 Other liabilities — 202 — 1,714 — 1,916 Total liabilities 3,972 192,990 14,297 180,598 (344,276 ) 47,581 Total shareholders' equity 52,063 29,018 45,604 96,786 (171,408 ) 52,063 Total liabilities and shareholders' equity $ 56,035 $ 222,008 $ 59,901 $ 277,384 $ (515,684 ) $ 99,644 Condensed Consolidating Balance Sheet July 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 85 $ 55 $ 2,920 $ — $ 3,060 Investments — — — 9,750 — 9,750 Accounts receivable, net — — — 5,357 — 5,357 Inventories — — — 3,580 — 3,580 Intercompany receivable 72 — 60 — (132 ) — Other current assets 5 — — 1,746 — 1,751 Total current assets 77 85 115 23,353 (132 ) 23,498 Property, plant, and equipment, net — — — 4,814 — 4,814 Goodwill — — — 41,309 — 41,309 Other intangible assets, net — — — 26,437 — 26,437 Tax assets — — — 1,232 — 1,232 Investment in subsidiaries 53,531 21,282 39,285 — (114,098 ) — Intercompany loans receivable 3,000 3,963 23,256 17,885 (48,104 ) — Other assets — — — 1,311 — 1,311 Total assets $ 56,608 $ 25,330 $ 62,656 $ 116,341 $ (162,334 ) $ 98,601 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ — $ 975 $ 972 $ — $ 1,947 Accounts payable — — — 1,615 — 1,615 Intercompany payable — — — 132 (132 ) — Accrued compensation 67 — — 1,138 — 1,205 Other accrued expenses 13 35 — 3,081 — 3,129 Total current liabilities 80 35 975 6,938 (132 ) 7,896 Long-term debt — 3,363 — 26,761 — 30,124 Accrued compensation and retirement benefits — — — 1,770 — 1,770 Accrued income taxes 10 — — 2,334 — 2,344 Long-term intercompany loans payable 5,626 4,107 15,152 23,219 (48,104 ) — Deferred tax liabilities — — — 3,790 — 3,790 Other liabilities — — — 1,785 — 1,785 Total liabilities 5,716 7,505 16,127 66,597 (48,236 ) 47,709 Shareholders’ equity 50,892 17,825 46,529 49,676 (114,098 ) 50,824 Noncontrolling interests — — — 68 — 68 Total equity $ 50,892 $ 17,825 $ 46,529 $ 49,744 $ (114,098 ) $ 50,892 Total liabilities and equity $ 56,608 $ 25,330 $ 62,656 $ 116,341 $ (162,334 ) $ 98,601 Condensed Consolidating Balance Sheet April 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 208 $ — $ 2,668 $ — $ 2,876 Investments — — — 9,758 — 9,758 Accounts receivable, net — — — 5,562 — 5,562 Inventories — — — 3,473 — 3,473 Intercompany receivable 403 — 61 — (464 ) — Other current assets 24 — — 1,907 — 1,931 Total current assets 427 208 61 23,368 (464 ) 23,600 Property, plant, and equipment, net — — 1 4,840 — 4,841 Goodwill — — — 41,500 — 41,500 Other intangible assets, net — — — 26,899 — 26,899 Tax assets — — — 1,383 — 1,383 Investment in subsidiaries 52,608 36,477 48,375 — (137,460 ) — Intercompany loans receivable 3,000 8,253 11,465 27,724 (50,442 ) — Other assets — — — 1,421 — 1,421 Total assets $ 56,035 $ 44,938 $ 59,902 $ 127,135 $ (188,366 ) $ 99,644 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 993 $ — $ 993 Accounts payable — — — 1,709 — 1,709 Intercompany payable — — — 464 (464 ) — Accrued compensation 32 — — 1,680 — 1,712 Other accrued expenses 12 24 — 2,715 — 2,751 Total current liabilities 44 24 — 7,561 (464 ) 7,165 Long-term debt — 3,382 — 26,727 — 30,109 Accrued compensation and retirement benefits — — — 1,759 — 1,759 Accrued income taxes 10 — — 2,893 — 2,903 Long-term intercompany loans payable 3,918 14,689 14,298 17,537 (50,442 ) — Deferred tax liabilities — — — 3,729 — 3,729 Other liabilities — — — 1,916 — 1,916 Total liabilities 3,972 18,095 14,298 62,122 (50,906 ) 47,581 Total shareholders' equity 52,063 26,843 45,604 65,013 (137,460 ) 52,063 Total liabilities and shareholders' equity $ 56,035 $ 44,938 $ 59,902 $ 127,135 $ (188,366 ) $ 99,644
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Three Months Ended July 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 440 $ 534 $ 13 $ 563 $ — $ 1,550 Investing Activities: Acquisitions, net of cash acquired — — — (12 ) — (12 ) Additions to property, plant, and equipment — — — (330 ) — (330 ) Purchases of investments — — — (1,206 ) 162 (1,044 ) Sales and maturities of investments — 162 — 1,104 (162 ) 1,104 Net (increase) decrease in intercompany loans — (541 ) (1,787 ) (785 ) 3,113 — Capital contribution paid — (162 ) — — 162 — Other investing activities, net — — — (2 ) — (2 ) Net cash provided by (used in) investing activities — (541 ) (1,787 ) (1,231 ) 3,275 (284 ) Financing Activities: Acquisition-related contingent consideration — — — (11 ) — (11 ) Change in current debt obligations, net — — 975 (49 ) — 926 Issuance of long-term debt — — — 33 — 33 Payments on long-term debt — — — (17 ) — (17 ) Dividends to shareholders (599 ) — — — — (599 ) Issuance of ordinary shares 214 — — — — 214 Repurchase of ordinary shares (1,763 ) — — — — (1,763 ) Net intercompany loan borrowings (repayments) 1,708 (2 ) 854 553 (3,113 ) — Capital contribution — — — 162 (162 ) — Other financing activities — — — 57 — 57 Net cash provided by (used in) financing activities (440 ) (2 ) 1,829 728 (3,275 ) (1,160 ) Effect of exchange rate changes on cash and cash equivalents — — — 78 — 78 Net change in cash and cash equivalents — (9 ) 55 138 — 184 Cash and cash equivalents at beginning of period — 55 — 2,821 — 2,876 Cash and cash equivalents at end of period $ — $ 46 $ 55 $ 2,959 $ — $ 3,060 Condensed Consolidating Statement of Cash Flows Three Months Ended July 31, 2015 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (2 ) $ (330 ) $ 178 $ 970 $ — $ 816 Investing Activities: Acquisitions, net of cash acquired — — — (179 ) — (179 ) Additions to property, plant, and equipment — (62 ) — (162 ) — (224 ) Purchases of investments — — — (1,851 ) — (1,851 ) Sales and maturities of investments — — — 1,266 — 1,266 Net (increase) decrease in intercompany loans (108 ) (99 ) (885 ) (135 ) 1,227 — Other investing activities, net — — — 2 — 2 Net cash provided by (used in) investing activities (108 ) (161 ) (885 ) (1,059 ) 1,227 (986 ) Financing Activities: Acquisition-related contingent consideration — — — (3 ) — (3 ) Change in current debt obligations, net — — 429 — — 429 Payments on long-term debt — — — (1,004 ) — (1,004 ) Dividends to shareholders (538 ) — — — — (538 ) Issuance of ordinary shares 98 — — — — 98 Repurchase of ordinary shares (750 ) — — — — (750 ) Net intercompany loan borrowings (repayments) 1,017 3 108 99 (1,227 ) — Other financing activities — — — 24 — 24 Net cash (used in) provided by financing activities (173 ) 3 537 (884 ) (1,227 ) (1,744 ) Effect of exchange rate changes on cash and cash equivalents — — — 50 — 50 Net change in cash and cash equivalents (283 ) (488 ) (170 ) (923 ) — (1,864 ) Cash and cash equivalents at beginning of period 263 1,071 170 3,339 — 4,843 Cash and cash equivalents at end of period $ (20 ) $ 583 $ — $ 2,416 $ — $ 2,979 Condensed Consolidating Statement of Cash Flows Three Months Ended July 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 440 $ (7 ) $ — $ 1,117 $ — $ 1,550 Investing Activities: Acquisitions, net of cash acquired — — — (12 ) — (12 ) Additions to property, plant, and equipment — — — (330 ) — (330 ) Purchases of investments — — — (1,044 ) — (1,044 ) Sales and maturities of investments — — — 1,104 — 1,104 Net (increase) decrease in intercompany loans receivable — 4,290 (1,774 ) 3,334 (5,850 ) — Capital contributions paid — (325 ) — — 325 — Other investing activities, net — — — (2 ) — (2 ) Net cash provided by (used in) investing activities — 3,965 (1,774 ) 3,050 (5,525 ) (284 ) Financing Activities: Acquisition-related contingent consideration — — — (11 ) — (11 ) Change in current debt obligations, net — — 975 (49 ) — 926 Issuance of long-term debt — — — 33 — 33 Payments on long-term debt — — — (17 ) — (17 ) Dividends to shareholders (599 ) — — — — (599 ) Issuance of ordinary shares 214 — — — — 214 Repurchase of ordinary shares (1,763 ) — — — — (1,763 ) Net intercompany loan borrowings (repayments) 1,708 (4,081 ) 854 (4,331 ) 5,850 — Intercompany dividend paid — — — — — — Capital contributions received — — — 325 (325 ) — Other financing activities — — — 57 — 57 Net cash provided by (used in) financing activities (440 ) (4,081 ) 1,829 (3,993 ) 5,525 (1,160 ) Effect of exchange rate changes on cash and cash equivalents — — — 78 — 78 Net change in cash and cash equivalents — (123 ) 55 252 — 184 Cash and cash equivalents at beginning of period — 208 — 2,668 — 2,876 Cash and cash equivalents at end of period $ — $ 85 $ 55 $ 2,920 $ — $ 3,060 Condensed Consolidating Statement of Cash Flows Three Months Ended July 31, 2015 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (2 ) $ 468 $ 374 $ 476 $ (500 ) $ 816 Investing Activities: Acquisitions, net of cash acquired — — — (179 ) — (179 ) Additions to property, plant, and equipment — — — (224 ) — (224 ) Purchases of investments — — — (1,851 ) — (1,851 ) Sales and maturities of investments — — — 1,266 — 1,266 Net (increase) decrease in intercompany loans receivable (108 ) (195 ) (1,081 ) (3,628 ) 5,012 — Other investing activities, net — — — 2 — 2 Net cash provided by (used in) investing activities (108 ) (195 ) (1,081 ) (4,614 ) 5,012 (986 ) Financing Activities: Acquisition-related contingent consideration — — — (3 ) — (3 ) Change in current debt obligations, net — — 429 — — 429 Issuance of long-term debt — — — — — — Payments on long-term debt — (1,000 ) — (4 ) — (1,004 ) Dividends to shareholders (538 ) — — — — (538 ) Issuance of ordinary shares 98 — — — — 98 Repurchase of ordinary shares (750 ) — — — — (750 ) Net intercompany loan borrowings (repayments) 1,017 179 108 3,708 (5,012 ) — Intercompany dividend paid — — — (500 ) 500 — Other financing activities — — — 24 — 24 Net cash provided by (used in) financing activities (173 ) (821 ) 537 3,225 (4,512 ) (1,744 ) Effect of exchange rate changes on cash and cash equivalents — — — 50 — 50 Net change in cash and cash equivalents (283 ) (548 ) (170 ) (863 ) — (1,864 ) Cash and cash equivalents at beginning of period 263 728 170 3,682 — 4,843 Cash and cash equivalents at end of period $ (20 ) $ 180 $ — $ 2,819 $ — $ 2,979

New Accounting Pronouncements (

New Accounting Pronouncements (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Apr. 29, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs	$ 133	$ 138
Excess tax benefits recognized in additional paid-in capital	57
Long-term debt [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs	133	138
Other assets [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs	$ (133)	$ (138)

Acquisitions and Acquisition-40

Acquisitions and Acquisition-Related Items - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 41,309	$ 41,500
2017 Acquisitions [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets	8
Property, plant, and equipment	5
Other intangible assets	48
Goodwill	56
Total assets acquired	117
Current liabilities	3
Deferred tax liabilities	3
Other liabilities	3
Total liabilities assumed	9
Net assets acquired	$ 108

Acquisitions and Acquisition-41

Acquisitions and Acquisition-Related Items - Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	$ 377	$ 264
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Beginning Balance	377	264
Purchase price contingent consideration	21	26
Payments	(14)	(3)
Change in fair value	(5)	4
Ending Balance	379	$ 291
Revenue-based payments [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	194
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Ending Balance	$ 194
Revenue-based payments [Member] | Minimum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate	11.00%
Probability of payment	30.00%
Revenue-based payments [Member] | Maximum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate	32.50%
Probability of payment	100.00%
Product development-based payments [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent Consideration, Fair Value	$ 185
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Ending Balance	$ 185
Product development-based payments [Member] | Minimum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate	0.30%
Probability of payment	75.00%
Product development-based payments [Member] | Maximum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate	5.50%
Probability of payment	100.00%

Acquisitions and Acquisition-42

Acquisitions and Acquisition-Related Items - Narrative (Details) - USD ($) $ in Millions	Aug. 23, 2016	Aug. 05, 2016	Jul. 29, 2016	Jul. 31, 2015	Apr. 29, 2016	Apr. 24, 2015
Business Acquisition [Line Items]
Acquisition-related items			$ 52	$ 71
Fair value of contingent consideration			379	$ 291	$ 377	$ 264
Other liabilities [Member]
Business Acquisition [Line Items]
Fair value of contingent consideration			321		311
Other accrued expenses [Member]
Business Acquisition [Line Items]
Fair value of contingent consideration			58		$ 66
Business combinations or purchases of intellectual property prior to April 24, 2009 [Member]
Business Acquisition [Line Items]
Maximum amount of future contingent consideration payments			$ 175
Subsequent Event [Member] | Heartware International, Inc. [Member]
Business Acquisition [Line Items]
Acquisition consideration	$ 1,100
Subsequent Event [Member] | Smith & Nephew's gynecology business [Member]
Business Acquisition [Line Items]
Acquisition consideration		$ 350

Restructuring Charges, Net - Re

Restructuring Charges, Net - Restructuring Reserve (Details) - Cost Synergies Initiative [Member] $ in Millions	3 Months Ended
	Jul. 29, 2016USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 250
Restructuring charges	111
Payments/write-downs	(98)
Reversal of excess accrual	(7)
Ending balance	256
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	213
Restructuring charges	77
Payments/write-downs	(68)
Reversal of excess accrual	(8)
Ending balance	214
Asset Write-downs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	0
Restructuring charges	14
Payments/write-downs	(14)
Reversal of excess accrual	0
Ending balance	0
Other Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	37
Restructuring charges	20
Payments/write-downs	(16)
Reversal of excess accrual	1
Ending balance	$ 42

Restructuring Charges, Net - Na

Restructuring Charges, Net - Narrative (Details) - Cost Synergies Initiative [Member] - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual	$ 7
Payments/write-downs	98
Asset write-downs [Member]
Restructuring Cost and Reserve [Line Items]
Reversal of excess accrual	0
Payments/write-downs	14
Impairment of property, plant and equipment [Member]
Restructuring Cost and Reserve [Line Items]
Payments/write-downs	4	$ 0
Covidien plc [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost synergies	850
Cost of products sold [Member] | Inventory write-offs [Member]
Restructuring Cost and Reserve [Line Items]
Payments/write-downs	$ 10

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Classification, and AFS in Continuous Loss Position (Details) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Available-for-sale securities:
Cost	$ 9,869	$ 10,000
Unrealized Gains	242	147
Unrealized Losses	(280)	(338)
Fair Value	9,831	9,809
Trading securities:
Cost	75	65
Unrealized Gains	19	15
Unrealized Losses	(1)	(1)
Fair Value	93	79
Cost method, equity method, and other investments:
Cost	546	506
Total investments [Abstract]
Cost	10,490	10,571
Unrealized Gains	261	162
Unrealized Losses	(281)	(339)
Fair Value	9,924	9,888
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	1,557	1,975
Less than 12 months, Unrealized Losses	(13)	(64)
More than 12 months, Fair Value	2,170	1,940
More than 12 months, Unrealized Losses	(267)	(275)
Investments [Member]
Available-for-sale securities:
Fair Value	9,657	9,679
Trading securities:
Fair Value	93	79
Cost method, equity method, and other investments:
Cost	0	0
Total investments [Abstract]
Fair Value	9,750	9,758
Other Assets [Member]
Available-for-sale securities:
Fair Value	174	130
Trading securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	546	506
Total investments [Abstract]
Fair Value	720	636
Level 1 [Member]
Available-for-sale securities:
Cost	760	867
Unrealized Gains	73	35
Unrealized Losses	(1)	(12)
Fair Value	832	890
Trading securities:
Cost	75	65
Unrealized Gains	19	15
Unrealized Losses	(1)	(1)
Fair Value	93	79
Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	703	805
Trading securities:
Fair Value	93	79
Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	129	85
Trading securities:
Fair Value	0	0
Level 2 [Member]
Available-for-sale securities:
Cost	9,061	9,085
Unrealized Gains	169	112
Unrealized Losses	(276)	(323)
Fair Value	8,954	8,874
Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	8,954	8,874
Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Level 3 [Member]
Available-for-sale securities:
Cost	48	48
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	45	45
Cost method, equity method, and other investments:
Cost	546	506
Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	0	0
Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	45	45
Cost method, equity method, and other investments:
Cost	546	506
Corporate debt securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	494	756
Less than 12 months, Unrealized Losses	(6)	(18)
More than 12 months, Fair Value	216	136
More than 12 months, Unrealized Losses	(8)	(6)
Corporate debt securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	4,113	3,935
Unrealized Gains	123	85
Unrealized Losses	(14)	(24)
Fair Value	4,222	3,996
Corporate debt securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	4,222	3,996
Corporate debt securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities [Member] | Level 3 [Member]
Available-for-sale securities:
Cost	1	1
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	1	1
Corporate debt securities [Member] | Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities [Member] | Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	1	1
U.S. government and agency securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value		308
Less than 12 months, Unrealized Losses		(4)
More than 12 months, Fair Value		67
More than 12 months, Unrealized Losses		(5)
U.S. government and agency securities [Member] | Level 1 [Member]
Available-for-sale securities:
Cost	675	792
Unrealized Gains	28	14
Unrealized Losses	0	(1)
Fair Value	703	805
U.S. government and agency securities [Member] | Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	703	805
U.S. government and agency securities [Member] | Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
U.S. government and agency securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	914	902
Unrealized Gains	3	2
Unrealized Losses	0	0
Fair Value	917	904
U.S. government and agency securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	917	904
U.S. government and agency securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	4	45
Less than 12 months, Unrealized Losses	(1)	(11)
More than 12 months, Fair Value	0	0
More than 12 months, Unrealized Losses	0	0
Marketable equity securities [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	129	85
Marketable equity securities [Member] | Level 1 [Member]
Available-for-sale securities:
Cost	85	75
Unrealized Gains	45	21
Unrealized Losses	(1)	(11)
Fair Value	129	85
Marketable equity securities [Member] | Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities [Member] | Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	129	85
Mortgage-backed securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	208	196
Less than 12 months, Unrealized Losses	(6)	(5)
More than 12 months, Fair Value	121	92
More than 12 months, Unrealized Losses	(10)	(5)
Mortgage-backed securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	917	1,016
Unrealized Gains	26	17
Unrealized Losses	(16)	(18)
Fair Value	927	1,015
Mortgage-backed securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	927	1,015
Mortgage-backed securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Foreign government and agency securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	15
Unrealized Gains	0
Unrealized Losses	0
Fair Value	15
Foreign government and agency securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	15
Foreign government and agency securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0
Other asset-backed securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	230	192
Unrealized Gains	3	3
Unrealized Losses	0	0
Fair Value	233	195
Other asset-backed securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	233	195
Other asset-backed securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Debt funds [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	851	670
Less than 12 months, Unrealized Losses	0	(26)
More than 12 months, Fair Value	1,789	1,601
More than 12 months, Unrealized Losses	(246)	(256)
Debt funds [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	2,872	3,040
Unrealized Gains	14	5
Unrealized Losses	(246)	(281)
Fair Value	2,640	2,764
Debt funds [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	2,640	2,764
Debt funds [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Auction rate securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	44	44
More than 12 months, Unrealized Losses	(3)	(3)
Auction rate securities [Member] | Level 3 [Member]
Available-for-sale securities:
Cost	47	47
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	44	44
Auction rate securities [Member] | Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Auction rate securities [Member] | Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	44	44
Exchange traded funds [Member] | Level 1 [Member]
Trading securities:
Cost	75	65
Unrealized Gains	19	15
Unrealized Losses	(1)	(1)
Fair Value	93	79
Exchange traded funds [Member] | Level 1 [Member] | Investments [Member]
Trading securities:
Fair Value	93	79
Exchange traded funds [Member] | Level 1 [Member] | Other Assets [Member]
Trading securities:
Fair Value	$ 0	$ 0

Financial Instruments - Unobser

Financial Instruments - Unobservable Inputs, and Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3) (Details) - Recurring [Member] - Level 3 [Member] - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 45	$ 106
Total unrealized losses included in other comprehensive income	0	(3)
Ending balance	45	103
Corporate Debt Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1	1
Total unrealized losses included in other comprehensive income	0	0
Ending balance	1	1
Auction Rate Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	44	105
Total unrealized losses included in other comprehensive income	0	(3)
Ending balance	$ 44	$ 102
Discounted cash flow [Member] | Auction Rate Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery	3 years
Illiquidity premium	6.00%
Minimum [Member] | Discounted cash flow [Member] | Auction Rate Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery	2 years
Maximum [Member] | Discounted cash flow [Member] | Auction Rate Securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery	12 years

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
AFS Debt Maturities
Due in one year or less	$ 969
Due after one year through five years	3,188
Due after five years through ten years	2,845
Due after ten years	60
Total	7,062
Debt [Member]
AFS Gross Realized Gain (Loss)
Proceeds from sales	1,098	$ 1,237
Gross realized gains	7	5
Gross realized losses	(12)	(5)
Impairment losses recognized	0	0
Equity [Member]
AFS Gross Realized Gain (Loss)
Proceeds from sales	6	29
Gross realized gains	4	12
Gross realized losses	0	0
Impairment losses recognized	$ (3)	$ (23)

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015	Apr. 29, 2016
Schedule of Investments [Line Items]
Marketable securities	$ 9,831		$ 9,809
Cost	546		506
Other expense, net [Member]
Schedule of Investments [Line Items]
Impairment, cost method investments	3	$ 0
Other assets [Member]
Schedule of Investments [Line Items]
Marketable securities	174		130
Cost	546		506
Debt securities [Member]
Schedule of Investments [Line Items]
Credit loss portion of other-than-temporary impairments	0		0
Reductions for available-for-sale securities sold	0	0
Other-than-temporary impairment losses on available-for-sale securities	0	0
Marketable equity securities [Member] | Other expense, net [Member]
Schedule of Investments [Line Items]
Impairment charges, marketable securities	0	$ 20
Marketable equity securities [Member] | Other assets [Member]
Schedule of Investments [Line Items]
Marketable securities	$ 129		$ 85

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Apr. 29, 2016
Debt Instrument [Line Items]
Debt premium	$ 198	$ 214
Deferred Financing Costs	(133)	(138)
Total Long-Term Debt	$ 30,124	30,109
Senior notes [Member] | 6.000 percent ten-year 2008 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.00%
Term of debt instrument	10 years
Long-term Debt	$ 1,150	1,150
Senior notes [Member] | 1.500 percent three-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	1.50%
Term of debt instrument	3 years
Long-term Debt	$ 1,000	1,000
Senior notes [Member] | 1.375 percent five-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	1.375%
Term of debt instrument	5 years
Long-term Debt	$ 1,000	1,000
Senior notes [Member] | 5.600 percent ten-year 2009 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	5.60%
Term of debt instrument	10 years
Long-term Debt	$ 400	400
Senior notes [Member] | 4.450 percent ten-year 2010 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.45%
Term of debt instrument	10 years
Long-term Debt	$ 766	766
Senior notes [Member] | 2.500 percent five-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.50%
Term of debt instrument	5 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | Floating rate five-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Term of debt instrument	5 years
Long-term Debt	$ 500	500
Senior notes [Member] | 4.200 percent ten-year 2010 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.20%
Term of debt instrument	10 years
Long-term Debt	$ 600	600
Senior notes [Member] | 4.125 percent ten-year 2011 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term Debt	$ 500	500
Senior notes [Member] | 3.125 percent ten-year 2012 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term Debt	$ 675	675
Senior notes [Member] | 3.150 percent seven-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | 3.200 percent ten-year 2012 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term Debt	$ 650	650
Senior notes [Member] | 2.750 percent ten-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term Debt	$ 530	530
Senior notes [Member] | 2.950 percent ten-year 2013 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term Debt	$ 310	310
Senior notes [Member] | 3.625 percent ten-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term Debt	$ 850	850
Senior notes [Member] | 3.500 percent ten-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term Debt	$ 4,000	4,000
Senior notes [Member] | 4.375 percent twenty-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term Debt	$ 2,382	2,382
Senior notes [Member] | 6.550 percent thirty-year 2008 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term Debt	$ 374	374
Senior notes [Member] | 6.500 percent thirty-year 2009 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term Debt	$ 300	300
Senior notes [Member] | 5.550 percent thirty-year 2010 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term Debt	$ 500	500
Senior notes [Member] | 4.500 percent thirty-year 2012 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term Debt	$ 400	400
Senior notes [Member] | 4.000 percent thirty-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term Debt	$ 325	325
Senior notes [Member] | 4.625 percent thirty-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term Debt	$ 650	650
Senior notes [Member] | 4.625 percent thirty-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term Debt	$ 4,000	4,000
Senior notes [Member] | Three-year term loan [Member]
Debt Instrument [Line Items]
Term of debt instrument	3 years
Long-term Debt	$ 3,000	3,000
Interest rate swaps [Member]
Debt Instrument [Line Items]
Long-term Debt	106	89
Capital lease obligations [Member]
Debt Instrument [Line Items]
Capital lease obligations	25	26
Bank borrowings [Member]
Debt Instrument [Line Items]
Long-term Debt	$ 66	$ 56

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details) - USD ($)	3 Months Ended
	Jul. 29, 2016	Apr. 29, 2016
Debt Instrument, Fair Value Disclosure [Abstract]
Long-term debt, including the current portion, fair value	$ 30,500,000,000	$ 29,800,000,000
Long-term debt, including the current portion, principal value	27,400,000,000	27,400,000,000
2015 Commercial Paper Program [Member] | Commercial Paper [Member]
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount	3,500,000,000
Commercial paper, amount outstanding	$ 975,000,000	0
Weighted average original maturity	21 days
Weighted average interest rate	0.73%
Amended and Restated Revolving Credit Agreement [Member] | Line of Credit [Member]
Line of Credit Facility
Line of credit, maximum capacity	$ 3,500,000,000
Term of debt instrument	5 years
Line of credit, amount outstanding	$ 0	$ 0

Derivatives and Foreign Excha51

Derivatives and Foreign Exchange Risk Management - Gains (Losses) on Derivatives and Amounts Reclassified into Income (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Other expense, net [Member] | Currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Currency exchange rate contracts (losses) gains	$ (3)	$ 20
Cash flow hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative		(14)
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income		74
Cash flow hedging [Member] | Currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gross Gains (Losses) Recognized in OCI on Effective Portion of Derivative	121	(14)
Cash flow hedging [Member] | Other expense, net [Member] | Currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income	$ 15	95
Cash flow hedging [Member] | Cost of products sold [Member] | Currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion of Gains (Losses) on Derivative Reclassified from AOCI into Income		$ (21)

Derivatives and Foreign Excha52

Derivatives and Foreign Exchange Risk Management - Location and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 388	$ 248
Liability Derivatives, Fair Value	250	219
Currency exchange rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	272	145
Liability Derivatives, Fair Value	169	166
Interest rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	106	89
Liability Derivatives, Fair Value	71	48
Commodity derivatives [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value		1
Cross currency interest rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	10	14
Liability Derivatives, Fair Value	10	4
Designated as hedging instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	352	221
Liability Derivatives, Fair Value	227	191
Designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	191	123
Designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	55	9
Designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	101	89
Designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	55	54
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	106	89
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	71	48
Not designated as hedging instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	36	27
Liability Derivatives, Fair Value	23	28
Not designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	26	13
Not designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	13	23
Not designated as hedging instrument [Member] | Commodity derivatives [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value		0
Not designated as hedging instrument [Member] | Commodity derivatives [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value		1
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	10	14
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 10	$ 4

Derivatives and Foreign Excha53

Derivatives and Foreign Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring [Member] - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	$ 272	$ 145
Derivative liabilities	169	166
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	116	103
Derivative liabilities	$ 81	$ 53

Derivatives and Foreign Excha54

Derivatives and Foreign Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	$ 388	$ 248
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(214)	(118)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(1)
Derivative Assets, Net Amount	174	129
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(250)	(219)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	214	119
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	26
Derivative Liabilities, Net Amount	(36)	(74)
Gross Amount of Recognized Assets (Liabilities)	138	29
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	1
Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	25
Net Amount	138	55
Currency exchange rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	272	145
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(189)	(98)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(1)
Derivative Assets, Net Amount	83	46
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(169)	(166)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	146	85
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	26
Derivative Liabilities, Net Amount	(23)	(55)
Interest rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	106	89
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(20)	(20)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Assets, Net Amount	86	69
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(71)	(48)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	63	34
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	(8)	(14)
Cross currency interest rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recognized Assets (Liabilities)	10	14
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(5)	0
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Assets, Net Amount	5	14
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)	(10)	(4)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	5	0
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	$ (5)	(4)
Commodity contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Liabilities, Gross Amount of Recognized Assets (Liabilities)		(1)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments		0
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted		0
Derivative Liabilities, Net Amount		$ (1)

Derivatives and Foreign Excha55

Derivatives and Foreign Exchange Risk Management - Narrative (Details) - USD ($)	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015	Apr. 29, 2016
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) relating to ineffectiveness of foreign currency cash flow hedges	$ 0	$ 0
Gain (losses) relating to ineffectiveness of forward starting interest rate derivatives	0	0
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	(36,000,000)		$ (90,000,000)
Cash flow hedge unrealized gains to be reclassified over the next 12 months	53,000,000
Gains (losses) on firm commitments that no longer qualify as fair value hedges	0	0
Gains (losses) relating to ineffectiveness of interest rate fair value hedges	0	0
Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss		74,000,000
Currency exchange rate contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	10,700,000,000		10,800,000,000
Currency exchange rate contracts [Member] | Not designated as hedging instrument [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	4,900,000,000		5,000,000,000
Currency exchange rate contracts [Member] | Designated as hedging instrument [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 5,800,000,000		5,700,000,000
Maximum remaining maturity of foreign currency derivatives	3 years
Interest rate swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Unrealized gains (losses) on outstanding forward starting interest rate swap derivative instruments	$ (71,000,000)		(48,000,000)
Interest rate swaps [Member] | Cash flow hedging [Member] | Interest expense, net [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	0	$ 0
Interest rate swaps [Member] | Designated as hedging instrument [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 300,000,000
Weighted average fixed rate of interest rate derivatives	3.10%
Interest rate swaps [Member] | Designated as hedging instrument [Member] | Fair Value Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 1,200,000,000		$ 1,200,000,000
Market value of outstanding interest rate swap agreements - net unrealized gain	106,000,000
Market value of hedged item - net unrealized loss	$ 106,000,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 2,346	$ 2,242
Work in-process	497	499
Raw materials	737	732
Total	$ 3,580	$ 3,473

Goodwill and Other Intangible57

Goodwill and Other Intangible Assets, Net - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	3 Months Ended
	Jul. 29, 2016USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 41,500
Goodwill as a result of acquisitions	56
Currency adjustment, net	(247)
Ending balance	41,309
Cardiac and Vascular Group [Member]
Goodwill [Roll Forward]
Beginning balance	6,243
Goodwill as a result of acquisitions	27
Currency adjustment, net	(11)
Ending balance	6,259
Minimally Invasive Therapies Group [Member]
Goodwill [Roll Forward]
Beginning balance	23,784
Goodwill as a result of acquisitions	(3)
Currency adjustment, net	(231)
Ending balance	23,550
Restorative Therapies Group [Member]
Goodwill [Roll Forward]
Beginning balance	9,620
Goodwill as a result of acquisitions	32
Currency adjustment, net	(5)
Ending balance	9,647
Diabetes Group [Member]
Goodwill [Roll Forward]
Beginning balance	1,853
Goodwill as a result of acquisitions	0
Currency adjustment, net	0
Ending balance	$ 1,853

Goodwill and Other Intangible58

Goodwill and Other Intangible Assets, Net - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	$ 31,027	$ 30,919
Accumulated Amortization	(5,228)	(4,741)
IPR&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	638	721
Customer-related [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	18,614	18,596
Accumulated Amortization	(1,596)	(1,331)
Purchased technology and patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	11,537	11,397
Accumulated Amortization	(3,173)	(2,976)
Trademarks and tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	804	854
Accumulated Amortization	(425)	(403)
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	72	72
Accumulated Amortization	$ (34)	$ (31)

Goodwill and Other Intangible59

Goodwill and Other Intangible Assets, Net - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Jul. 29, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2,017	$ 1,449
2,018	1,905
2,019	1,811
2,020	1,763
2,021	1,746
2,022	$ 1,705

Goodwill and Other Intangible60

Goodwill and Other Intangible Assets, Net - Narrative (Details) - USD ($)	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0
Impairment of definite-lived intangible assets	0	0
Impairment of indefinite-lived intangible assets	0	0
Amortization expense	$ 487,000,000	$ 481,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015	Apr. 29, 2016
Income Tax Disclosure [Abstract]
Income tax expense (benefit) - certain tax adjustments	$ (31)
Income tax expense (benefit) - intercompany debt issues	(431)
Income tax expense (benefit) - acquisition-related issues	371
Income tax expense (benefit) - redemption of an intercompany minority interest	$ 29
Effective tax rate from continuing operations	6.00%	12.80%
Gross unrecognized tax benefits	$ 1,900		$ 2,700
Accrued income tax interest and penalties	261
Unrecognized tax benefits that would impact effective tax rate	$ 1,800

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Numerator:
Net income attributable to ordinary shareholders	$ 929	$ 820
Denominator:
Basic weighted average shares outstanding (shares)	1,392.2	1,418.1
Effect of dilutive securities:
Employee stock options (shares)	10.5	13.2
Employee restricted stock units (shares)	3.9	5
Other (shares)	0.5	0.1
Diluted weighted average shares outstanding (shares)	1,407.1	1,436.4
Basic earnings per share (usd per share)	$ 0.67	$ 0.58
Diluted earnings per share (usd per share)	$ 0.66	$ 0.57
Stock options and restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	5	20
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	4	1
Restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	1	1

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 79	$ 96
Income tax benefits	(21)	(29)
Total stock-based compensation expense, net of tax	58	67
Cost of products sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	11	12
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	9	8
Selling, general and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	51	49
Restructuring charges, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1	8
Acquisition-related items [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	7	19
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	38	57
Restricted stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	34	34
Employee stock purchase plan shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 7	$ 5

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
U.S. Pension Benefits [Member]
Net Periodic Benefit Cost
Service cost	$ 29	$ 30
Interest cost	27	31
Expected return on plan assets	(47)	(45)
Amortization of net actuarial loss	23	24
Net periodic benefit cost	32	40
Non-U.S. Pension Benefits [Member]
Net Periodic Benefit Cost
Service cost	19	22
Interest cost	6	9
Expected return on plan assets	(12)	(13)
Amortization of net actuarial loss	4	6
Net periodic benefit cost	$ 17	$ 24

Accumulated Other Comprehensi65

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure - Changes in AOCI (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	$ 52,063
Other comprehensive loss	(156)	$ (172)
Balance	50,824
Unrealized Gain (Loss) on Available-for-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	(107)	14
Other comprehensive income (loss) before reclassifications, before tax	168	(193)
Tax expense	(52)	70
Other comprehensive income (loss) before reclassifications, net of tax	116	(123)
Reclassifications, before tax	(1)	(12)
Tax (expense) benefit	0	4
Reclassifications, net of tax	(1)	(8)
Other comprehensive loss	115	(131)
Balance	8	(117)
Cumulative Translation Adjustments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	(474)	(277)
Other comprehensive income (loss) before reclassifications, before tax	(350)	(26)
Tax expense	0	0
Other comprehensive income (loss) before reclassifications, net of tax	(350)	(26)
Reclassifications, before tax	0	0
Tax (expense) benefit	0	0
Reclassifications, net of tax	0	0
Other comprehensive loss	(350)	(26)
Balance	(824)	(303)
Net Change in Retirement Obligations [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	(1,197)	(1,131)
Other comprehensive income (loss) before reclassifications, before tax	0	(7)
Tax expense	0	0
Other comprehensive income (loss) before reclassifications, net of tax	0	(7)
Reclassifications, before tax	27	30
Tax (expense) benefit	(2)	(10)
Reclassifications, net of tax	25	20
Other comprehensive loss	25	13
Balance	(1,172)	(1,118)
Unrealized Gain (Loss) on Derivatives [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	(90)	210
Other comprehensive income (loss) before reclassifications, before tax	98	14
Tax expense	(36)	(6)
Other comprehensive income (loss) before reclassifications, net of tax	62	8
Reclassifications, before tax	(14)	(62)
Tax (expense) benefit	6	26
Reclassifications, net of tax	(8)	(36)
Other comprehensive loss	54	(28)
Balance	(36)	182
Total Accumulated Other Comprehensive (Loss) Income [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance	(1,868)	(1,184)
Other comprehensive income (loss) before reclassifications, before tax	(84)	(212)
Tax expense	(88)	64
Other comprehensive income (loss) before reclassifications, net of tax	(172)	(148)
Reclassifications, before tax	12	(44)
Tax (expense) benefit	4	20
Reclassifications, net of tax	16	(24)
Other comprehensive loss	(156)	(172)
Balance	$ (2,024)	$ (1,356)

Accumulated Other Comprehensi66

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure - Supplemental Equity Schedule (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 52,063
Net income	929	$ 820
Other comprehensive loss	(156)	$ (172)
Dividends to shareholders	(599)
Issuance of shares under stock purchase and award plans	214
Repurchase of ordinary shares	(1,763)
Tax benefit from exercise of stock-based awards	57
Stock-based compensation	79
Additions of noncontrolling ownership interests	68
Balance	50,892
Total Shareholders' Equity [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	52,063
Net income	929
Other comprehensive loss	(156)
Dividends to shareholders	(599)
Issuance of shares under stock purchase and award plans	214
Repurchase of ordinary shares	(1,763)
Tax benefit from exercise of stock-based awards	57
Stock-based compensation	79
Balance	50,824
Noncontrolling Interests [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	0
Additions of noncontrolling ownership interests	68
Balance	$ 68

Commitments and Contingencies (

Commitments and Contingencies (Details)	Sep. 01, 2016claim	Dec. 14, 2011patent	Aug. 19, 2010landfill	Jun. 29, 2007	Jul. 31, 2015USD ($)claim	Jul. 29, 2016USD ($)claim	Jul. 31, 2015USD ($)	Apr. 29, 2016USD ($)	Apr. 26, 2013USD ($)
Loss Contingencies [Line Items]
Certain litigation charges						$ 82,000,000	$ 0
Accrued certain litigation charges						1,100,000,000		$ 1,000,000,000
Covidien plc [Member]
Loss Contingencies [Line Items]
Tax sharing percentage, parent				42.00%
Tax sharing percentage, former parent				27.00%
Tax sharing percentage, former affiliate				31.00%
Orrington, Maine chemical manufacturing facility [Member]
Loss Contingencies [Line Items]
Number of landfills requiring removal | landfill			2
Number of landfills requiring capping | landfill			3
Penobscot River and Bay remediation [Member]
Loss Contingencies [Line Items]
Low cost estimate for potential remediation						25,000,000
High cost estimate for potential remediation						$ 235,000,000
Indemnification agreement [Member] | Covidien plc [Member] | Tax Years Prior To 2013 [Member]
Loss Contingencies [Line Items]
Maximum potential loss for tax indemnification									$ 200,000,000
INFUSE [Member] | Product liability litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | claim						6,000
INFUSE [Member] | Product liability litigation [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of claims settled | claim	4,300
Pelvic mesh [Member] | Product liability litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | claim						15,800
Number of claims settled | claim					11,000
Settlement receivable					$ 121,000,000
Pelvic mesh [Member] | Product liability litigation [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of claims settled | claim	6,200
Ethicon [Member]
Loss Contingencies [Line Items]
Patents infringed | patent		1

Segment and Geographic Inform68

Segment and Geographic Information (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Segment Reporting Information [Line Items]
Net sales	$ 7,166	$ 7,274
Income before Income Taxes by Reportable Segment
Restructuring charges, net	(94)	(67)
Certain litigation charges	(82)	0
Acquisition-related items	(52)	(71)
Interest expense, net	(179)	(191)
Income from operations before income taxes	988	940
Americas [Member]
Segment Reporting Information [Line Items]
Net sales	4,297	4,445
U.S. [Member]
Segment Reporting Information [Line Items]
Net sales	4,000	4,100
EMEA [Member]
Segment Reporting Information [Line Items]
Net sales	1,650	1,669
Asia Pacific [Member]
Segment Reporting Information [Line Items]
Net sales	822	770
Greater China [Member]
Segment Reporting Information [Line Items]
Net sales	397	390
Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	1,558	1,749
Segment Reconciling Items [Member]
Income before Income Taxes by Reportable Segment
Impact of inventory step-up	0	(226)
Restructuring charges, net	(104)	(67)
Certain litigation charges	(82)	0
Acquisition-related items	(52)	(71)
Interest expense, net	(179)	(191)
Corporate, Non-Segment [Member]
Income before Income Taxes by Reportable Segment
Corporate	(153)	(254)
Cardiac and Vascular Group [Member]
Segment Reporting Information [Line Items]
Net sales	2,518	2,567
Cardiac and Vascular Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	656	817
Minimally Invasive Therapies Group [Member]
Segment Reporting Information [Line Items]
Net sales	2,424	2,456
Minimally Invasive Therapies Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	283	334
Restorative Therapies Group [Member]
Segment Reporting Information [Line Items]
Net sales	1,772	1,806
Restorative Therapies Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	507	481
Diabetes Group [Member]
Segment Reporting Information [Line Items]
Net sales	452	445
Diabetes Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	$ 112	$ 117

Guarantor Financial Informati69

Guarantor Financial Information - Narrative (Details) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016	Apr. 24, 2015
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	$ 0	$ 0
Shareholders’ equity	50,824	52,063
Intercompany payable	0	0
Intercompany receivable	0	0
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	70,405	68,902
Shareholders’ equity	29,589	29,018
Intercompany payable	152,269	151,687
Intercompany receivable	140,906	141,368
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	21,282	36,477
Shareholders’ equity	17,825	26,843
Intercompany payable	0	0
Intercompany receivable	0	0
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	53,531	52,608
Shareholders’ equity	50,892	52,063
Intercompany payable	0	0
Intercompany receivable	72	403
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	53,531	52,608
Shareholders’ equity	50,892	52,063
Intercompany payable	0	0
Intercompany receivable	72	403
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	40,609	49,698
Shareholders’ equity	46,529	45,604
Intercompany payable	0	0
Intercompany receivable	0	0
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	39,285	48,375
Shareholders’ equity	46,529	45,604
Intercompany payable	0	0
Intercompany receivable	60	61
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	0	0
Shareholders’ equity	88,582	96,786
Intercompany payable	152,145	152,362
Intercompany receivable	163,436	162,278
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries	0	0
Shareholders’ equity	49,676	65,013
Intercompany payable	132	464
Intercompany receivable	$ 0	$ 0
Error correction, Covidien acquisition [Member] | Subsidiary Issuer [Member] | Medtronic Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries			$ 5,100
Shareholders’ equity			5,100
Error correction, Covidien acquisition [Member] | Subsidiary Issuer [Member] | CIFSA Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries			(5,100)
Shareholders’ equity			(5,100)
Error correction, intercompany balances [Member] | Subsidiary Issuer [Member] | Medtronic Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Shareholders’ equity			(20,500)
Intercompany receivable			(20,500)
Error correction, intercompany balances [Member] | Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries			(20,500)
Intercompany payable			(20,500)
Error correction, intercompany balances [Member] | Subsidiary Guarantors [Member] | Medtronic Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries			(20,500)
Shareholders’ equity			(20,500)
Error correction, intercompany balances [Member] | Subsidiary Guarantors [Member] | CIFSA Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries			(20,500)
Shareholders’ equity			(20,500)
Error correction, intercompany balances [Member] | Subsidiary Non-guarantors [Member] | CIFSA Notes [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Shareholders’ equity			(20,500)
Intercompany receivable			$ (20,500)

Guarantor Financial Informati70

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Condensed Statement of Income Captions [Line Items]
Net sales	$ 7,166	$ 7,274
Costs and expenses:
Cost of products sold	2,261	2,456
Research and development expense	556	558
Selling, general, and administrative expense	2,428	2,449
Restructuring charges, net	94	67
Certain litigation charges	82	0
Acquisition-related items	52	71
Amortization of intangible assets	487	481
Other (income) expense, net	39	61
Operating profit	1,167	1,131
Interest income	(93)	(115)
Interest expense	272	306
Interest expense, net	179	191
Equity in net (income) loss of subsidiaries	0	0
Income from operations before income taxes	988	940
Provision (benefit) for income taxes	59	120
Net income	929	820
Other comprehensive income (loss), net of tax	(156)	(172)
Comprehensive income	773	648
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	(348)	(373)
Costs and expenses:
Cost of products sold	(354)	(346)
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Restructuring charges, net	0	0
Certain litigation charges	0
Acquisition-related items	0	0
Amortization of intangible assets	0	0
Other (income) expense, net	0	0
Operating profit	6	(27)
Interest income	405	245
Interest expense	(405)	(245)
Interest expense, net	0	0
Equity in net (income) loss of subsidiaries	3,005	2,508
Income from operations before income taxes	(2,999)	(2,535)
Provision (benefit) for income taxes	0	0
Net income	(2,999)	(2,535)
Other comprehensive income (loss), net of tax	233	544
Comprehensive income	(2,766)	(1,991)
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Restructuring charges, net	0	0
Certain litigation charges	0
Acquisition-related items	0	0
Amortization of intangible assets	0	0
Other (income) expense, net	0	0
Operating profit	0	0
Interest income	199	351
Interest expense	(199)	(351)
Interest expense, net	0	0
Equity in net (income) loss of subsidiaries	2,563	1,674
Income from operations before income taxes	(2,563)	(1,674)
Provision (benefit) for income taxes	0	0
Net income	(2,563)	(1,674)
Other comprehensive income (loss), net of tax	270	410
Comprehensive income	(2,293)	(1,264)
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	3	2
Restructuring charges, net	0	0
Certain litigation charges	0
Acquisition-related items	0	0
Amortization of intangible assets	0	0
Other (income) expense, net	11	73
Operating profit	(14)	(75)
Interest income	0	0
Interest expense	16	1
Interest expense, net	16	1
Equity in net (income) loss of subsidiaries	(957)	(890)
Income from operations before income taxes	927	814
Provision (benefit) for income taxes	(2)	(6)
Net income	929	820
Other comprehensive income (loss), net of tax	(156)	(172)
Comprehensive income	773	648
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold		0
Research and development expense	0	0
Selling, general, and administrative expense	3	2
Restructuring charges, net	0	0
Certain litigation charges	0
Acquisition-related items	0	0
Amortization of intangible assets	0	0
Other (income) expense, net	11	73
Operating profit	(14)	(75)
Interest income	0	0
Interest expense	16	1
Interest expense, net	16	1
Equity in net (income) loss of subsidiaries	(957)	(890)
Income from operations before income taxes	927	814
Provision (benefit) for income taxes	(2)	(6)
Net income	929	820
Other comprehensive income (loss), net of tax	(156)	(172)
Comprehensive income	773	648
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	348	373
Costs and expenses:
Cost of products sold	250	256
Research and development expense	163	162
Selling, general, and administrative expense	280	249
Restructuring charges, net	16	2
Certain litigation charges	0
Acquisition-related items	23	35
Amortization of intangible assets	3	3
Other (income) expense, net	(640)	(388)
Operating profit	253	54
Interest income	(60)	(64)
Interest expense	408	444
Interest expense, net	348	380
Equity in net (income) loss of subsidiaries	(1,246)	(911)
Income from operations before income taxes	1,151	585
Provision (benefit) for income taxes	22	(162)
Net income	1,129	747
Other comprehensive income (loss), net of tax	95	(153)
Comprehensive income	1,224	594
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Restructuring charges, net	0	0
Certain litigation charges	0
Acquisition-related items	0	0
Amortization of intangible assets	0	0
Other (income) expense, net	1	0
Operating profit	(1)	0
Interest income	(29)	(164)
Interest expense	32	36
Interest expense, net	3	(128)
Equity in net (income) loss of subsidiaries	(805)	(77)
Income from operations before income taxes	801	205
Provision (benefit) for income taxes	0	0
Net income	801	205
Other comprehensive income (loss), net of tax	42	(66)
Comprehensive income	843	139
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Restructuring charges, net	0	0
Certain litigation charges	0
Acquisition-related items	0	0
Amortization of intangible assets	0	0
Other (income) expense, net	0	0
Operating profit	0	0
Interest income	(156)	(183)
Interest expense	1	0
Interest expense, net	(155)	(183)
Equity in net (income) loss of subsidiaries	(802)	(707)
Income from operations before income taxes	957	890
Provision (benefit) for income taxes	0	0
Net income	957	890
Other comprehensive income (loss), net of tax	(156)	(172)
Comprehensive income	801	718
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0
Costs and expenses:
Cost of products sold	0	0
Research and development expense	0	0
Selling, general, and administrative expense	0	0
Restructuring charges, net	0	0
Certain litigation charges	0
Acquisition-related items	0	0
Amortization of intangible assets	0	0
Other (income) expense, net	0	0
Operating profit	0	0
Interest income	(157)	(184)
Interest expense	1	1
Interest expense, net	(156)	(183)
Equity in net (income) loss of subsidiaries	(801)	(707)
Income from operations before income taxes	957	890
Provision (benefit) for income taxes	0	0
Net income	957	890
Other comprehensive income (loss), net of tax	(156)	(172)
Comprehensive income	801	718
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	7,166	7,274
Costs and expenses:
Cost of products sold	2,365	2,546
Research and development expense	393	396
Selling, general, and administrative expense	2,145	2,198
Restructuring charges, net	78	65
Certain litigation charges	82
Acquisition-related items	29	36
Amortization of intangible assets	484	478
Other (income) expense, net	668	376
Operating profit	922	1,179
Interest income	(282)	(113)
Interest expense	252	106
Interest expense, net	(30)	(7)
Equity in net (income) loss of subsidiaries	0	0
Income from operations before income taxes	952	1,186
Provision (benefit) for income taxes	39	288
Net income	913	898
Other comprehensive income (loss), net of tax	(172)	(219)
Comprehensive income	741	679
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	7,166	7,274
Costs and expenses:
Cost of products sold	2,261	2,456
Research and development expense	556	558
Selling, general, and administrative expense	2,425	2,447
Restructuring charges, net	94	67
Certain litigation charges	82
Acquisition-related items	52	71
Amortization of intangible assets	487	481
Other (income) expense, net	27	(12)
Operating profit	1,182	1,206
Interest income	(106)	(118)
Interest expense	422	619
Interest expense, net	316	501
Equity in net (income) loss of subsidiaries	0	0
Income from operations before income taxes	866	705
Provision (benefit) for income taxes	61	126
Net income	805	579
Other comprehensive income (loss), net of tax	(156)	(172)
Comprehensive income	$ 649	$ 407

Guarantor Financial Informati71

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Jul. 29, 2016	Apr. 29, 2016	Jul. 31, 2015	Apr. 24, 2015
Current assets:
Cash and cash equivalents	$ 3,060	$ 2,876	$ 2,979	$ 4,843
Investments	9,750	9,758
Accounts receivable, net	5,357	5,562
Inventories	3,580	3,473
Intercompany receivable	0	0
Other current assets	1,751	1,931
Total current assets	23,498	23,600
Property, plant, and equipment, net	4,814	4,841
Goodwill	41,309	41,500
Other intangible assets, net	26,437	26,899
Tax assets	1,232	1,383
Investment in subsidiaries	0	0
Intercompany loans receivable	0	0
Other assets	1,311	1,421
Total assets	98,601	99,644
Current liabilities:
Current debt obligations	1,947	993
Accounts payable	1,615	1,709
Intercompany payable	0	0
Accrued compensation	1,205	1,712
Other accrued expenses	3,129	2,751
Total current liabilities	7,896	7,165
Long-term debt	30,124	30,109
Accrued compensation and retirement benefits	1,770	1,759
Accrued income taxes	2,344	2,903
Long-term intercompany loans payable	0	0
Deferred tax liabilities	3,790	3,729
Other liabilities	1,785	1,916
Total liabilities	47,709	47,581
Shareholders’ equity	50,824	52,063
Noncontrolling interests	68	0
Total equity	50,892	52,063
Total liabilities and equity	98,601	99,644
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	(194)	(200)
Intercompany receivable	(304,414)	(304,049)
Other current assets	(29)	0
Total current assets	(304,637)	(304,249)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(164,545)	(171,208)
Intercompany loans receivable	(63,340)	(40,227)
Other assets	0	0
Total assets	(532,522)	(515,684)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(304,414)	(304,049)
Accrued compensation	0	0
Other accrued expenses	0	0
Total current liabilities	(304,414)	(304,049)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	(63,340)	(40,227)
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	(367,754)	(344,276)
Shareholders’ equity	(164,768)	(171,408)
Noncontrolling interests	0
Total equity	(164,768)
Total liabilities and equity	(532,522)	(515,684)
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	(132)	(464)
Other current assets	0	0
Total current assets	(132)	(464)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(114,098)	(137,460)
Intercompany loans receivable	(48,104)	(50,442)
Other assets	0	0
Total assets	(162,334)	(188,366)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(132)	(464)
Accrued compensation	0	0
Other accrued expenses	0	0
Total current liabilities	(132)	(464)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	(48,104)	(50,442)
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	(48,236)	(50,906)
Shareholders’ equity	(114,098)	(137,460)
Noncontrolling interests	0
Total equity	(114,098)
Total liabilities and equity	(162,334)	(188,366)
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	0	0	(20)	263
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	72	403
Other current assets	5	24
Total current assets	77	427
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	53,531	52,608
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	56,608	56,035
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	67	32
Other accrued expenses	13	12
Total current liabilities	80	44
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Long-term intercompany loans payable	5,626	3,918
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	5,716	3,972
Shareholders’ equity	50,892	52,063
Noncontrolling interests	0
Total equity	50,892
Total liabilities and equity	56,608	56,035
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	0	0	(20)	263
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	72	403
Other current assets	5	24
Total current assets	77	427
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	53,531	52,608
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	56,608	56,035
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	67	32
Other accrued expenses	13	12
Total current liabilities	80	44
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Long-term intercompany loans payable	5,626	3,918
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	5,716	3,972
Shareholders’ equity	50,892	52,063
Noncontrolling interests	0
Total equity	50,892
Total liabilities and equity	56,608	56,035
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	46	55	583	1,071
Investments	0	0
Accounts receivable, net	0	0
Inventories	153	162
Intercompany receivable	140,906	141,368
Other current assets	178	271
Total current assets	141,283	141,856
Property, plant, and equipment, net	1,166	1,139
Goodwill	0	0
Other intangible assets, net	28	31
Tax assets	699	690
Investment in subsidiaries	70,405	68,902
Intercompany loans receivable	9,425	8,884
Other assets	540	506
Total assets	223,546	222,008
Current liabilities:
Current debt obligations	500	500
Accounts payable	339	288
Intercompany payable	152,269	151,687
Accrued compensation	362	616
Other accrued expenses	615	243
Total current liabilities	154,085	153,334
Long-term debt	26,669	26,646
Accrued compensation and retirement benefits	1,319	1,258
Accrued income taxes	1,522	1,422
Long-term intercompany loans payable	10,125	10,128
Deferred tax liabilities	0	0
Other liabilities	237	202
Total liabilities	193,957	192,990
Shareholders’ equity	29,589	29,018
Noncontrolling interests	0
Total equity	29,589
Total liabilities and equity	223,546	222,008
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	85	208	180	728
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	0	0
Other current assets	0	0
Total current assets	85	208
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	21,282	36,477
Intercompany loans receivable	3,963	8,253
Other assets	0	0
Total assets	25,330	44,938
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Other accrued expenses	35	24
Total current liabilities	35	24
Long-term debt	3,363	3,382
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	4,107	14,689
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	7,505	18,095
Shareholders’ equity	17,825	26,843
Noncontrolling interests	0
Total equity	17,825
Total liabilities and equity	25,330	44,938
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	55	0	0	170
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	0	0
Other current assets	0	0
Total current assets	55	0
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	40,609	49,698
Intercompany loans receivable	21,991	10,203
Other assets	0	0
Total assets	62,655	59,901
Current liabilities:
Current debt obligations	975	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Other accrued expenses	0	0
Total current liabilities	975	0
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	15,151	14,297
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	16,126	14,297
Shareholders’ equity	46,529	45,604
Noncontrolling interests	0
Total equity	46,529
Total liabilities and equity	62,655	59,901
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	55	0	0	170
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	60	61
Other current assets	0	0
Total current assets	115	61
Property, plant, and equipment, net	0	1
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	39,285	48,375
Intercompany loans receivable	23,256	11,465
Other assets	0	0
Total assets	62,656	59,902
Current liabilities:
Current debt obligations	975	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Other accrued expenses	0	0
Total current liabilities	975	0
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	15,152	14,298
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	16,127	14,298
Shareholders’ equity	46,529	45,604
Noncontrolling interests	0
Total equity	46,529
Total liabilities and equity	62,656	59,902
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Current assets:
Cash and cash equivalents	2,959	2,821	2,416	3,339
Investments	9,750	9,758
Accounts receivable, net	5,357	5,562
Inventories	3,621	3,511
Intercompany receivable	163,436	162,278
Other current assets	1,597	1,636
Total current assets	186,720	185,566
Property, plant, and equipment, net	3,648	3,702
Goodwill	41,309	41,500
Other intangible assets, net	26,409	26,868
Tax assets	533	693
Investment in subsidiaries	0	0
Intercompany loans receivable	28,924	18,140
Other assets	771	915
Total assets	288,314	277,384
Current liabilities:
Current debt obligations	472	493
Accounts payable	1,276	1,421
Intercompany payable	152,145	152,362
Accrued compensation	776	1,064
Other accrued expenses	2,501	2,496
Total current liabilities	157,170	157,836
Long-term debt	3,455	3,463
Accrued compensation and retirement benefits	451	501
Accrued income taxes	812	1,471
Long-term intercompany loans payable	32,438	11,884
Deferred tax liabilities	3,790	3,729
Other liabilities	1,548	1,714
Total liabilities	199,664	180,598
Shareholders’ equity	88,582	96,786
Noncontrolling interests	68
Total equity	88,650
Total liabilities and equity	288,314	277,384
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Current assets:
Cash and cash equivalents	2,920	2,668	$ 2,819	$ 3,682
Investments	9,750	9,758
Accounts receivable, net	5,357	5,562
Inventories	3,580	3,473
Intercompany receivable	0	0
Other current assets	1,746	1,907
Total current assets	23,353	23,368
Property, plant, and equipment, net	4,814	4,840
Goodwill	41,309	41,500
Other intangible assets, net	26,437	26,899
Tax assets	1,232	1,383
Investment in subsidiaries	0	0
Intercompany loans receivable	17,885	27,724
Other assets	1,311	1,421
Total assets	116,341	127,135
Current liabilities:
Current debt obligations	972	993
Accounts payable	1,615	1,709
Intercompany payable	132	464
Accrued compensation	1,138	1,680
Other accrued expenses	3,081	2,715
Total current liabilities	6,938	7,561
Long-term debt	26,761	26,727
Accrued compensation and retirement benefits	1,770	1,759
Accrued income taxes	2,334	2,893
Long-term intercompany loans payable	23,219	17,537
Deferred tax liabilities	3,790	3,729
Other liabilities	1,785	1,916
Total liabilities	66,597	62,122
Shareholders’ equity	49,676	65,013
Noncontrolling interests	68
Total equity	49,744
Total liabilities and equity	$ 116,341	$ 127,135

Guarantor Financial Informati72

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 29, 2016	Jul. 31, 2015
Operating Activities:
Net cash provided by (used in) operating activities	$ 1,550	$ 816
Investing Activities:
Acquisitions, net of cash acquired	(12)	(179)
Additions to property, plant, and equipment	(330)	(224)
Purchases of investments	(1,044)	(1,851)
Sales and maturities of investments	1,104	1,266
Net (increase) decrease in intercompany loans	0	0
Capital contribution paid	0
Other investing activities, net	(2)	2
Net cash used in investing activities	(284)	(986)
Financing Activities:
Acquisition-related contingent consideration	(11)	(3)
Change in current debt obligations, net	926	429
Issuance of long-term debt	33	0
Payments on long-term debt	(17)	(1,004)
Dividends to shareholders	(599)	(538)
Issuance of ordinary shares	214	98
Repurchase of ordinary shares	(1,763)	(750)
Net intercompany loan borrowings (repayments)	0	0
Intercompany dividend paid	0	0
Capital contribution	0
Other financing activities	57	24
Net cash used in financing activities	(1,160)	(1,744)
Effect of exchange rate changes on cash and cash equivalents	78	50
Net change in cash and cash equivalents	184	(1,864)
Cash and cash equivalents at beginning of period	2,876	4,843
Cash and cash equivalents at end of period	3,060	2,979
Consolidating Adjustments [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	162	0
Sales and maturities of investments	(162)	0
Net (increase) decrease in intercompany loans	3,113	1,227
Capital contribution paid	162
Other investing activities, net	0	0
Net cash used in investing activities	3,275	1,227
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(3,113)	(1,227)
Capital contribution	(162)
Other financing activities	0	0
Net cash used in financing activities	(3,275)	(1,227)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	0	(500)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	(5,850)	5,012
Capital contribution paid	325
Other investing activities, net	0	0
Net cash used in investing activities	(5,525)	5,012
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	5,850	(5,012)
Intercompany dividend paid	0	500
Capital contribution	(325)
Other financing activities	0	0
Net cash used in financing activities	5,525	(4,512)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	440	(2)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	0	(108)
Capital contribution paid	0
Other investing activities, net	0	0
Net cash used in investing activities	0	(108)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	(599)	(538)
Issuance of ordinary shares	214	98
Repurchase of ordinary shares	(1,763)	(750)
Net intercompany loan borrowings (repayments)	1,708	1,017
Capital contribution	0
Other financing activities	0	0
Net cash used in financing activities	(440)	(173)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	(283)
Cash and cash equivalents at beginning of period	0	263
Cash and cash equivalents at end of period	0	(20)
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	440	(2)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	0	(108)
Capital contribution paid	0
Other investing activities, net	0	0
Net cash used in investing activities	0	(108)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	(599)	(538)
Issuance of ordinary shares	214	98
Repurchase of ordinary shares	(1,763)	(750)
Net intercompany loan borrowings (repayments)	1,708	1,017
Intercompany dividend paid	0	0
Capital contribution	0
Other financing activities	0	0
Net cash used in financing activities	(440)	(173)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	(283)
Cash and cash equivalents at beginning of period	0	263
Cash and cash equivalents at end of period	0	(20)
Subsidiary Issuer [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	534	(330)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	(62)
Purchases of investments	0	0
Sales and maturities of investments	162	0
Net (increase) decrease in intercompany loans	(541)	(99)
Capital contribution paid	(162)
Other investing activities, net	0	0
Net cash used in investing activities	(541)	(161)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(2)	3
Capital contribution	0
Other financing activities	0	0
Net cash used in financing activities	(2)	3
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(9)	(488)
Cash and cash equivalents at beginning of period	55	1,071
Cash and cash equivalents at end of period	46	583
Subsidiary Issuer [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(7)	468
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	4,290	(195)
Capital contribution paid	(325)
Other investing activities, net	0	0
Net cash used in investing activities	3,965	(195)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	(1,000)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(4,081)	179
Intercompany dividend paid	0	0
Capital contribution	0
Other financing activities	0	0
Net cash used in financing activities	(4,081)	(821)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(123)	(548)
Cash and cash equivalents at beginning of period	208	728
Cash and cash equivalents at end of period	85	180
Subsidiary Guarantors [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	13	178
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	(1,787)	(885)
Capital contribution paid	0
Other investing activities, net	0	0
Net cash used in investing activities	(1,787)	(885)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	975	429
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	854	108
Capital contribution	0
Other financing activities	0	0
Net cash used in financing activities	1,829	537
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	55	(170)
Cash and cash equivalents at beginning of period	0	170
Cash and cash equivalents at end of period	55	0
Subsidiary Guarantors [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	0	374
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	(1,774)	(1,081)
Capital contribution paid	0
Other investing activities, net	0	0
Net cash used in investing activities	(1,774)	(1,081)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	975	429
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	854	108
Intercompany dividend paid	0	0
Capital contribution	0
Other financing activities	0	0
Net cash used in financing activities	1,829	537
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	55	(170)
Cash and cash equivalents at beginning of period	0	170
Cash and cash equivalents at end of period	55	0
Subsidiary Non-guarantors [Member] | Medtronic Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	563	970
Investing Activities:
Acquisitions, net of cash acquired	(12)	(179)
Additions to property, plant, and equipment	(330)	(162)
Purchases of investments	(1,206)	(1,851)
Sales and maturities of investments	1,104	1,266
Net (increase) decrease in intercompany loans	(785)	(135)
Capital contribution paid	0
Other investing activities, net	(2)	2
Net cash used in investing activities	(1,231)	(1,059)
Financing Activities:
Acquisition-related contingent consideration	(11)	(3)
Change in current debt obligations, net	(49)	0
Issuance of long-term debt	33
Payments on long-term debt	(17)	(1,004)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	553	99
Capital contribution	162
Other financing activities	57	24
Net cash used in financing activities	728	(884)
Effect of exchange rate changes on cash and cash equivalents	78	50
Net change in cash and cash equivalents	138	(923)
Cash and cash equivalents at beginning of period	2,821	3,339
Cash and cash equivalents at end of period	2,959	2,416
Subsidiary Non-guarantors [Member] | CIFSA Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	1,117	476
Investing Activities:
Acquisitions, net of cash acquired	(12)	(179)
Additions to property, plant, and equipment	(330)	(224)
Purchases of investments	(1,044)	(1,851)
Sales and maturities of investments	1,104	1,266
Net (increase) decrease in intercompany loans	3,334	(3,628)
Capital contribution paid	0
Other investing activities, net	(2)	2
Net cash used in investing activities	3,050	(4,614)
Financing Activities:
Acquisition-related contingent consideration	(11)	(3)
Change in current debt obligations, net	(49)	0
Issuance of long-term debt	33	0
Payments on long-term debt	(17)	(4)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(4,331)	3,708
Intercompany dividend paid	0	(500)
Capital contribution	325
Other financing activities	57	24
Net cash used in financing activities	(3,993)	3,225
Effect of exchange rate changes on cash and cash equivalents	78	50
Net change in cash and cash equivalents	252	(863)
Cash and cash equivalents at beginning of period	2,668	3,682
Cash and cash equivalents at end of period	$ 2,920	$ 2,819